XVII MEDITERRANEAN CONGRESS OF RHEUMATOLOGY

EFFECTS OF THE DIET AND THE CLIMATE IN RHEUMATIC AND MUSCULOSKELETAL DISEASES

PRELIMINARY PROGRAM
PATRONAGES

European League Against the Rheumatism (EULAR)

Italian Society of Rheumatology
(Società Italiana di Reumatologia – SIR)

The University Of Genoa

The Department of internal medicine and medical specialities (DiMI)
University of Genoa

The Region Liguria

The IRCCS Polyclinic Hospital San Martino Genoa

The Metropolitan City of Genoa

The City of Genoa
From at least 2,000 years the Mediterranean area with the connected Black and Red Sea populations has been the “CRIB” of the culture, science and good life.

What means good life?

What means good life? Good life mean an acceptable style of life, even modest but healthy, and of course, it includes good food and good climate! Today, we recognize that, among the multiple risk factors involved in the development of several diseases, environmental and nutritional components play an important role. The rheumatic diseases are among the most common diseases in the general population and the effects of wrong diets and non healthy environment/style of life, are recognized as important promoters for their development. Correct diet represents also part of a correct management of the Rheumatic & Musculoskeletal Diseases. Already from the beginning, the Mediterranean Congress of Rheumatology has presented the experiences regarding the characteristics of the Rheumatic Diseases in such area, and comparing their epidemiology among the European countries. This 2018 edition of the Congress will focus about the effects of the diet and the climate on the most frequent Rheumatic and Musculoskeletal Diseases, including their early diagnosis and advanced therapies. The Congress topics will be discussed in sequential sessions and will include appropriate presentations on nutritional and environmental factors that will integrate the clinical and drug treatment lectures. Of course, participants will have the occasion to taste personally in spring time, the therapeutical effects of the mediterranean diet and climate “available” for all participants during the Congress that will be held in the Old Harbour of Genoa.

CONGRESS CHAIRPERSON

M. Cutolo Genoa, Italy
On the behalf of the Board of the Mediterranean Congress of Rheumatology and of Italian Society of Rheumatology

XVII MEDITERRANEAN CONGRESS SCIENTIFIC BOARD

N. Akkoc Izmir, Turkey
L. Carmona Madrid, Spain
B. Combe Montpellier, France
N. Damjanov Belgrade, Serbia
L. Denisov Moscow, Russia
J.E. Fonseca Lisbon, Portugal
M. Gattorno Genoa, Italy
S. Grazio Zagreb, Croatia
A. Iagnocco Turin, Italy
M. Inanc Istanbul, Turkey
G.D. Kitas Manchester, UK
M. Kouloumas Nicosia, Cyprus
P. Sfikakis Athens, Greece
Y. Shoenfeld Tel Aviv, Israel
S. Sokolovic Sarajevo, Bosnia and Herzegovina
S.G. Sukkar Genoa, Italy
Z. Szekanecz Debrecen, Hungary
A. Tzioufas Athens, Greece
ADVISORS

INTERNATIONAL ADVISORS

N. Akkoc Izmir, Turkey
S. Aligrutic Podgorica, Montenegro
A. Alunno Perugia, Italy
B. Anic Zagreb, Croatia
S. Ataman Ankara, Turkey
M. Reda Awad Agouza, Giza, Egypt
H. Bassiouni, Cairo, Egypt
S. Bombardieri Pisa, Italy
J.W.J. Bijlsma Utrecht, The Netherlands
D. Boumpas Athens, Greece
G.R. Burmester Berlin, Germany
L. Carmona Madrid, Spain
C. Christodoulou Larnaca, Cyprus
B. Coleiro Birkirkara, Malta
B. Combe Montpellier, France
J.A.P. Da Silva Coimbra, Portugal
N. Damjanov Belgrade, Serbia
L. Denisov Moscow, Russia
A. Dinc Çankaya, Turkey
H. Direskeneli Istanbul, Turkey
A. Doria Padua, Italy
A. El Garf Cairo, Egypt
O. Elkayam Tel Aviv, Israel
K. Elmuntaser Tripoli, Libya
J.E. Fonseca Lisbon, Portugal
M. Gattorno Genoa, Italy
S. Grazio Zagreb, Croatia
A. Gul Istanbul, Turkey
N. Hajjaj-Hassouni Rabat, Morocco
I. Holc Maribor, Slovenia
A. Iagnocco Turin, Italy
M. Inanc Istanbul, Turkey
R. Ionescu Bucharest, Romania
L. Kazkaz Damascus, Syria
G.D. Kitas Manchester, UK
M. Kouloumas Nicosia, Cyprus
E.J. Kucharz Katowice, Poland
A. Ladjouze Algiers, Algeria
C. Mallia Msida, Malta
X. Mariette Paris, France
A. Martini Genoa, Italy
M. Matucci Cerinic Florence, Italy
I. McInnes Glasgow, UK
G. Minisola Rome, Italy
P. Miossec Lyon, France
S. Mishevska-Percinkova Skopje, Republic of Macedonia
C. Montecucco Pavia, Italy
M. Mosca Pisa, Italy
E. Nasonov Moscow, Russia
E. Nikiphorou London, UK
C.H. Opava Huddinge, Sweden
N. Prodanovic Banja Luka, Republic of Srpska - Bosnia Herzegovina
R. Rashkov Sofia, Bulgaria
A. Ravelli Genoa, Italy
P. Sarzi Puttini Milan, Italy
J. Sellam Paris, France
P. Sfikakis Athens, Greece
Y. Shoenfeld Tel Aviv, Israel
V. Smith Ghent, Belgium
S. Sokolovic Sarajevo, Bosnia and Herzegovina
R. Straub Regensburg, Germany
S.G. Sukkar Genoa, Italy
Z. Szekanecz Debrecen, Hungary
A. Tafaj Tirana, Albania
M. Tishler Zrifin, Israel
A. Tzioufas Athens, Greece
I. Uthman Beirut, Lebanon
D. Wiek Hünxe, Germany
H. Yazici Istanbul, Turkey
D. Vassilopoulos Athens, Greece
L. Zakraoui Tunis, Tunisia
NATIONAL ADVISORS

S. Antonelli Rome, Italy
G. Arioli Mantua, Italy
G. Bajocchi Reggio Emilia, Italy
M. Bentivegna Ragusa, Italy
R. Caporali Pavia, Italy
S. D’Angelo Potenza, Italy
L. Di Matteo Pescara, Italy
M. Galeazzi Siena, Italy
R. Gerli Perugia, Italy
A. Mathieu Cagliari, Italy
I. Olivieri† Potenza, Italy
L. Quartuccio Udine, Italy
F. Salaffi Ancona, Italy
G. Sebastiani Rome, Italy
L. Sinigaglia Milan, Italy
A. Tincani Brescia, Italy
G. Valesini Rome, Italy

LOCAL ADVISORS

P. Comanducci
Rector University of Genoa
M. Amore
Dean School of Medicine University of Genoa
G. Ucci
CEO of the Polyclinic Hospital San Martino
G. La Valle
Chief Medical Officer of the Polyclinic Hospital San Martino
S. Viale
CEO Health System & Vice President of Liguria Government
M. Bucci
Major of the City of Genoa
S. Balleari
Vice Major of the City of Genoa
P. Odetti
Director Medical Department - DiMI – University of Genoa
S.G. Sukkar
Director Clinical Nutrition Polyclinic Hospital San Martino
S. Ferrero
Congress Medical Link Officer at the Liguria Government
M. Cutolo
Director Division of Rheumatology – DiMI

MEDICAL TEAM

A. Sulli
S. Paolino
C. Pizzorni
M. Ghio
B. Ruaro
M.A Cimmino
# Preliminary Timetable

## Thursday 12th April, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Platea Maestrale Room</th>
<th>Levante-Ponente Room</th>
<th>Libeccio Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Opening Registrations and Exhibition</td>
<td>NOT ACCREDITED</td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>OPENING CEREMONY</td>
<td>NOT ACCREDITED</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>LECTURE: The diet in autoimmune rheumatic diseases: a recipe for therapy?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>FIRST SESSION: Early Rheumatoid Arthritis</td>
<td>related ORAL COMMUNICATIONS</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>SECOND SESSION: Mediterranean Diet in the 3rd Millennium: Just Prevention or even Therapy?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>LECTURE: Epigenetics effects of the Mediterranean Diet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>START THE POSTER EXHIBITION</td>
<td>NOT ACCREDITED</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>LECTURE: Gouty Arthritis and diastemalombism</td>
<td>related ORAL COMMUNICATIONS</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>LECTURE: Metabolic effects of Glucocorticoids: is there a safe dosage?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Friday 13th April, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Platea Maestrale Room</th>
<th>Levante-Ponente Room</th>
<th>Libeccio Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>THIRD SESSION: Osteoarthritis and its management</td>
<td>related ORAL COMMUNICATIONS</td>
<td>PEDIATRIC SESSION: Pediatric Rheumatology In the Mediterranean area</td>
</tr>
<tr>
<td>08:45</td>
<td>FOURTH SESSION: Autoinflammatory and Rare Connective Tissue Diseases</td>
<td>related ORAL COMMUNICATIONS</td>
<td>PATIENT SESSION: Pregnancy in IIMT: what the patients would you like to know NOT ACCREDITED</td>
</tr>
<tr>
<td>11:00</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>Industry - Sponsored SATELLITE LECTURE</td>
<td>Industry - Sponsored SATELLITE LECTURE</td>
<td>NOT ACCREDITED</td>
</tr>
<tr>
<td>15:00</td>
<td>Industry - Sponsored SATELLITE SYMPOSIUM</td>
<td>Industry - Sponsored SATELLITE SYMPOSIUM</td>
<td>NOT ACCREDITED</td>
</tr>
<tr>
<td>16:00</td>
<td>POSTER TOUR</td>
<td>NOT ACCREDITED</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
We invite all Congress participants to attend the seven Lectures which will be held during Thursday 12 April and Friday 13 April, 2018. Nine Scientific Sessions and related Oral communications will be held over the three days. Other interesting Sessions dedicated to Patients will take place between Friday and Saturday; a Pediatric Session on Friday, as well the SPECIAL Ultrasound Session will run in parallel to the other Scientific Sessions on Saturday.

Industry - Sponsored Satellite Lectures and Satellite Symposia will occupy the slots from 11.20 to 12.50 on Friday 13 April, 2018.

Poster Exhibition and Tour are planned before afternoon Coffee break on Thursday 12 April and before lunch on Friday 13 April.
IMPORTANT NOTICE for Scientific Sessions

We invite all Congress participants to attend the nine Scientific Sessions which will be held during Thursday 12, Friday 13 and Saturday 14 April, 2018 into the “Platea Maestrale” Room. Each Session will focus on the priority themes listed below. In parallel with each Session will correspond the related Oral Communication Session.

- Epidemiology, nutritional aspects and environmental factors
- The early disease: clinical features and diagnostic tools
- Management: from guidelines up to the last treatment issues
- Management: non pharmacological aspects and unmet needs

The speeches which differ from the above mentioned titles and thematic are indicated in the following Program.

---

Thursday, April 12th 2018

13.30 – 14.00  Platea Maestrale Room [NO CME ACTIVITY]
OPENING CEREMONY
Welcome from Local Academic, Hospital and Government Authorities

14.00 – 14.30  Platea Maestrale Room
LECTURE - The diet in rheumatic autoimmune diseases: a recipe for therapy?
Speaker: 
Y. Shoenfeld (Chair for Research of Autoimmune Diseases, Tel-Aviv University, Israel; Head of the Mosaic of Autoimmunity Project, Saint Petersburg State University)
Chair: 
M. Cutolo (Genoa, Italy)

14.30 - 15.40  Platea Maestrale Room
FIRST SESSION: Early Rheumatoid Arthritis
Speakers:
14.30  Epidemiology, nutritional aspects and environmental factors
I. McInnes (Glasgow, UK)
14.45  The early disease: clinical features and diagnostic tools
G. Burmester (Berlin, Germany)
15.00  Management: from guidelines up to the last treatment issues
B. Combe (Montpellier, France)
15.15  Management: non pharmacological aspects and unmet needs
Z. Szekanecz (Debrecen, Hungary)

Chairs:
G. Burmester (Berlin, Germany), C. Montecucco (Pavia, Italy)
FIRST SESSION: Early Rheumatoid Arthritis

Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman's introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion.

Oral Communications:

OC1:1 VACCINATIONS IN INFLAMMATORY ARTHRITIS PATIENTS
S. Khan (Dublin, Ireland)

OC1:2 MULTICENTER CROSS-SECTIONAL STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS IN GREECE. RESULTS FROM A COHORT OF 2,491 PATIENTS
K. Thomas (Athens, Greece)

OC1:3 THE ROLE OF DIET ON RHEUMATOID ARTHRITIS: WHAT DO CLINICAL TRIALS TELL US?
S. Petersson (Nicosia, Cyprus)

OC1:4 FACTORS ASSOCIATED WITH PROGRESSION TO INFLAMMATORY ARTHRITIS IN THE FIRST-DEGREE RELATIVES (FDR) OF INDIGENOUS NORTH AMERICAN (INA) RA PATIENTS
H. El-Gabalawy (Winnipeg, Canada)

OC1:5 SALT CONSUMPTION MAY BE A RISK FACTOR FOR THE DEVELOPMENT OF ARTHRITIS
L. Carmona (Madrid, Spain)

OC1:6 DIETETIC THERAPY AND RHEUMATOID ARTHRITIS
tbd

Chair – INTRODUCTION:
R. Caporali (Pavia, Italy)

15.40 – 16.10 Platea Maestrale Room

LECTURE - Mediterranean Diet in the 3rd Millennium: Just Prevention or even Therapy?

Speaker:
A. Trichopoulou (Athens, Greece)

Chair:
S.G. Sukkar (Genoa, Italy)

16.10 – 16.40 Platea Maestrale Room

LECTURE - Epigenetic Effects of the Mediterranean Diet

Speaker:
A. Martinez (Pamplona, Spain)

Chair:
S.G. Sukkar (Genoa, Italy)

16.40 – 17.10 Poster Area

NO CME ACTIVITY

START THE POSTER EXHIBITION

16.40 – 17.10 Poster and Exhibition Area

Coffee break
SECOND SESSION: Gouty arthritis and dismetabolism

Speakers:

17.10  Nutritional aspects - including weight loss - for gout: an update from clinical epidemiology
S. M. Nielson (Copenhagen, Denmark)

17.25  The early disease: clinical features and diagnostic tools
F. Sivera (Alicante, Spain)

17.40  Management: from guidelines up to the last treatment issues
P. Richette (Paris, France)

17.55  Management: non pharmacological aspects and unmet needs
L. Punzi (Padua, Italy)

Chairs:
L. Punzi (Padua, Italy), P. Richette (Paris, France)

SECOND SESSION: Gouty arthritis and dismetabolism
Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman's introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

Oral Communications:

OC2:1  EFFECT OF POLYDATIN AND RESVERATROL ON CRYSTAL-INDUCED INFLAMMATION: BENEFICIAL IMPLICATIONS FOR GOUT AND OTHER CRYSTAL-RELATED ARTHROPATHIES
F. Oliviero (Padua, Italy)

OC2:2  ANALYSIS OF THE EFFICACY OF LOW PURINE DIET IN GOUT PATIENTS
M.S. Eliseev (Moscow, Russia)

OC2:3  COMBINATION OF LOSARTAN AND ALLOPURINOL IN HYPERTENSIVE PATIENTS WITH HYPERURICEMIA
M. Jordhani (Tirana, Albania)

OC2:4  ULTRA-LOW DOSEANTI-INTERLEUKIN1 IN CHRONIC GOUT: A SAFE AND SUCCESSFUL COMBINATION THERAPY WITH LOW DOSE COLCHICINE AND URATE LOWERING AGENTS
M. Capassoni (Florence, Italy)

OC2:5  SEASONAL VARIATION OF JOINT ASPIRATIONS FOR GOUT AND CPPD IN A COHORT OF ARTROPATHIC PATIENTS WITH EFFUSION
M. A. Cimmino (Genoa, Italy)

OC2:6  GOUT AND METABOLIC SYNDROME
N. Zehraoui (Algiers, Algeria)

Chair - INTRODUCTION:
S. Grazio (Zagreb, Croatia)

LECTURE - Metabolic effects of Glucocorticoids: is there a safe dosage?

Speaker:
J.W.J. Bijlsma (Utrecht, The Netherlands)

Chair:
M. Cutofo (Genoa, Italy)
**Friday, April 13th 2018**

8.30 - 9.40  
**Platea Maestrale Room**

**THIRD SESSION: Osteoarthritis and its management**

**Speakers:**

8.30  
Epidemiology, nutritional aspects and environmental factors  
**C. Scire (Ferrara, Italy)**

8.45  
The early disease: new aspects on the role of imaging  
**A. Iagnocco (Turin, Italy)**

9.00  
Management: from guidelines up to the last treatment issues  
**J.Y Reginster (Liège, Belgium)**

9.15  
Management: non pharmacological aspects and unmet needs  
**P. Sarzi-Puttini (Milan, Italy)**

**Chairs:**

**M. Galeazzi (Siena, Italy), J.Y. Reginster (Liège, Belgium)**

8.30 - 9.40  
**Levante – Ponente Room**

**THIRD SESSION: Osteoarthritis and its management**

**Concomitant Session and related Oral Communications**

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

**Oral Communications:**

**OC3:1**  
MUTUAL INTERACTION BETWEEN OXIDATIVE STRESS AND MICRORNAS. AN IN VITRO STUDY ON HUMAN OSTEOARTHRITIC CHONDROCYTE CULTURES  
**S. Cheleschi (Siena, Italy)**

**OC3:2**  
KNEE ARTHRITIS AND METABOLIC SYNDROM  
**D. Dusa (Constanta, Romania)**

**OC3:3**  
VISCOSUPPLEMENTATION IN NON-SEVERE KNEE OSTEOARTHRITIS: A NETWORK META-ANALYSIS OF HIGH QUALITY RANDOMIZED CLINICAL TRIALS  
**L. Carmona (Madrid, Spain)**

**OC3:4**  
MUD-BATH THERAPY REGULATES THE EXPRESSION LEVELS OF MICRORNAS IN OSTEOARTHRITIS. EPIGENETIC CONTRIBUTION TO EXPLAIN THE MECHANISM OF ACTION OF BALNEOTHERAPY  
**S. Cheleschi (Siena, Italy)**

**OC3:5**  
PATIENTS PERCEPTION OF PAIN IN OSTEOARTHRITIS: RESULTS OF A ROUMANIAN SURVEY  
**I. Saulescu (Bucharest, Romania)**

**OC3:6**  
KNEE EXTENSOR MUSCLE WEAKNESS AND RADIOGRAPHIC KNEE OSTEOARTHRITIS PROGRESSION  
**A. Dell’isola (Glasgow, United Kingdom), (Savona, Italy)**

**Chair – INTRODUCTION:**

**G. Sebastiani (Rome, Italy)**

8.30 – 09.40  
**Libeccio Room**

**Pediatric Rheumatology in the Mediterranean area**

**Concomitant Session**

**Speakers:**

08.30  
Multinational Study on epidemiology, treatment and outcome of children with idiopathic juvenile arthritis  
**A. Ravelli (Genoa, Italy)**
Longitudinal evaluation of growth and puberty development in pediatric rheumatic diseases

N. Ruperto (Genoa, Italy)

Discussion

A. Martini (Genoa, Italy), A. Ravelli (Genoa, Italy)

FOURTH SESSION: Autoinflammatory and Rare Connective Tissue Diseases

Speakers:

9.40 Autoinflammatory diseases: diagnostic criteria, guidelines and advances
M. Gattorno (Genoa, Italy)

9.55 Focus on familial Mediterranean fever
H. Lachmann (London, UK)

10.10 Beyond for the vasculitis risk in the Mediterranean
A. Gul (Istanbul, Turkey)

10.25 Focus on Behçet disease
L. Cantarini (Siena, Italy)

10.40 NEWS – 5 minutes Short report on a new European Project- ERN, on Rare Connective Tissue Diseases – ReCONNET
M. Mosca (Pisa, Italy)

Chairs:
M. Gattorno (Genoa, Italy), H. Lachmann (London, UK)

FOURTH SESSION: Autoinflammatory and Rare Connective Tissue Diseases

Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

Oral Communications:

OC4:1 A GENETIC COHORT STUDY TO GENOTYPE SEVERAL INTERLEUKIN GENE POLYMORPHISMS IN A GROUP OF BEHÇET’S SYNDROME PATIENTS LIVING IN THE MEDITERRANEAN AREA
M.C. Padula (Potenza, Italy)

OC4:2 ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS IN M.L. Popescu (Bucharest, Romania)

OC4:3 CAN AUTOANTIBODIES PREDICT OUTCOMES OR SURVIVAL IN INTERSTITIAL LUNG DISEASE?: RESULTS FROM A RETROSPECTIVE COHORT STUDY IN GREECE.
A. Venetsanopoulou (Athens, Greece)

OC4:4 BIRMINGHAM VASCULITIS ACTIVITY INDEX (BVAS) A USEFUL TOOL IN DISEASE ACTIVITY IN BEHÇET’S DISEASE
C. Buzatu (Bucharest, Romania)

OC4:5 A SEASONAL ONSET FOR POLYMYALGIA RHEUMATICA?
E. Hysa (Genoa, Italy)

OC4:6 ASSESSMENT OF ORGAN DAMAGE ACCORDING TO IMACS (INTERNATIONAL MYOSITIS ASSESSMENT AND CLINICAL STUDIES) MYOSITIS DAMAGE INDEX IN 92 PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS
M. Inanc (Istanbul, Turkey)

Chair – INTRODUCTION:
M. Inanc (Istanbul, Turkey)
PATIENT SESSION:

**Pregnancy in RMDs: what the patients would like to know**

SESSIONE DEDICATA AI PAZIENTI: Gravidanza e malattie reumatiche: quello che il malato vorrebbe sapere

**Concomitant Session**

**Speakers:**

- **LECTURE: Pregnancy yes in RMDs**
  - **A. Tincani** *(Brescia, Italy)*

- **LECTURE: Lettura: Pregnancy No in RMDs**
  - **L. Andreoli** *(Brescia, Italy)*

**Chair:**

- **A. Tincani** *(Brescia, Italy)*

**Poster and Exhibition Area**

**Coffee break**

**11.20 – 11.50**

**Platea Maestrale Room / Levante – Ponente Room**

**Concomitants Industry - Sponsored SATELLITE LECTURES**

**NO CME ACTIVITY**

**11.50 – 12.50**

**Platea Maestrale Room / Levante – Ponente Room**

**Concomitants Industry - Sponsored SATELLITE SYMPOSIA**

**NO CME ACTIVITY**

**12.50 – 14.00**

**Poster Area**

**NO CME ACTIVITY**

**POSTER TOUR**

**13.00 – 14.00**

**Poster and Exhibition Area**

**Lunch**

**14.00 -14.30**

**Platea Maestrale Room**

**LECTURE - Sun, vitamin D and rheumatic diseases**

**Speaker:**

- **M. Cutolo** *(Genoa, Italy)*

**Chair:**

- **G. Minisola** *(Rome, Italy)*

**14.00 – 16.40**

**Libeccio Room**

**NO CME ACTIVITY**

**YOUNG PATIENTS AND RHEUMATOLOGISTS SESSION:**

**The impact of nutrition and lifestyle on RMDS**

**Concomitant Session**

**Speakers:**

- **People’s perceptions on nutritional aspects and rheumatic disease:**
  - Completion of the **“Truth or myth”** questionnaire by the audience

- **Nutrition and rheumatic disease: are we really what we eat?**

  - **E. Philippou** *(Nicosia, Cyprus – London, UK)*
14.30 The sun and rheumatic disease: friend or foe?
M. Cutolo (Genoa, Italy)

14.50 The impact of diet in rheumatic diseases
C. Dairen (Montpellier, France)

15.10 Analysis and sharing of the results of the “Truth or myth” questionnaire at the end of the Session

15.20 ‘Your 5-a-dA’ VIDEO for a healthy and ‘joint-friendly’ exercise regime that can be undertaken as part of the daily routine
L. Bacoccoli - Personal trainer Virgin Active Village (Perugia, Italy)

15.30 Workshop – Problem based cases and discussion (Participants will be divided in groups)
M. Kouloumas (Nicosia, Cyprus), D. Wiek (Hünxe, Germany)

Chairs: A. Alunno (Perugia, Italy), M. Kouloumas (Nicosia, Cyprus), E. Nikiphorou (London, UK), D. Wiek (Hünxe, Germany)

14.30 – 15.00 Platea Maestrale Room
Lecture - Fostering physical activity together with correct nutrition: a successful approach but rarely respected in RMDs
Speaker:
G.D. Kitas (Manchester, UK)
Chair:
S. Bombardieri (Pisa, Italy)

15.00 – 16.10 Platea Maestrale Room
FIFTH SESSION: From Raynaud’s phenomenon up to Systemic Sclerosis
Speakers:
15.00 Epidemiology, nutritional aspects and environmental factors
U. Muller-Lardner (Bad Nauheim, Germany)

15.15 The early disease: clinical features and diagnostic tools
M. Matucci Cerinic (Florence, Italy)

15.30 Management: from guidelines up to the last treatment issues
C. Denton (London, UK)

15.45 Management: non pharmacological aspects and unmet needs
O. Distler (Zurich, Switzerland)

Chairs:
C. Denton (London, Uk), V. Smith (Ghent, Belgium)

15.00 – 16.10 Levante – Ponente Room
FIFTH SESSION: From Raynaud’s phenomenon up to Systemic Sclerosis
Concomitant Session and related Oral Communications
Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

Oral Communications:
OC5:1 ASSOCIATION OF INTERLEUKIN-17 AND INTERLEUKIN-23 MRNA AND PROTEIN EXPRESSION PROFILES WITH CLINICAL PRESENTATION IN PATIENTS WITH SYSTEMIC SCLEROSIS
A. Zekovic (Belgrade, Serbia)
VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS: CORRELATIONS WITH MULTIPLE CLINICAL PARAMETERS, SEASONAL VARIATIONS AND TREATMENT EFFECTIVENESS IN EUROPEAN SSC PATIENTS  
A. C. Trombetta (Genoa, Italy)

TYPE I INTERFERON INDUCED GENE EXPRESSION IN THE PERIPHERAL BLOOD OF PATIENTS WITH SYSTEMIC SCLEROSIS  
N. Vlachogiannis (Athens, Greece)

CORRELATIONS BETWEEN SKIN BLOOD PERFUSION AND CHOROIDAL THICKNESS IN SYSTEMIC SCLEROSIS PATIENTS BEFORE AND AFTER A SHORT TIME TREATMENT WITH PROSTACYCLIN ANALOGUE  
A. Sulli (Genoa, Italy)

RELIABILITY OF SIMPLE CAPILLAROSCOPIC DEFINITIONS TO DESCRIBE CAPILLARY MORPHOLOGY IN RHEUMATIC DISEASES  
A. Vanhaecke (Ghent, Belgium)

MACITENTAN CONTRASTS THE ACTIVATION OF PROFIBROTIC INTRACELLULAR SIGNALING PATHWAYS INDUCED BY ENDOTHELIN-1 IN PRIMARY CULTURES OF SKIN FIBROBLASTS ISOLATED FROM HEALTHY SUBJECTS  
S. Soldano (Genoa, Italy)

Chair – INTRODUCTION:  
A. Sulli (Genoa, Italy)

16.10 – 16.40 Platea Maestrale Room
LECTURE - Balneotherapy and RMDs: when, where and how to choose  
Speaker:  
A. Fioravanti (Siena, Italy)
Chair:  
T. Bender (Budapest, Hungary)

16.40 – 17.10 Poster and Exhibition Area
Coffee break

17.10 – 18.30 Platea Maestrale Room
SIXTH SESSION: Systemic Lupus Erythematosus and related syndromes  
Speakers:  
17.10 Epidemiology, nutritional aspects and environmental factors  
G. Bertsias (Heraklion - Crete, Greece)
17.25 The early disease: clinical features and diagnostic investigations  
D. Boumpas (Athens, Greece)
17.40 Management: from guidelines up to the last treatment issues  
A. Doria (Padua, Italy)
18.00 The antiphospholipid syndrome: news on management and unmet needs  
A. Tincani (Brescia, Italy)

Chairs:  
D. Boumpas (Athens, Greece), M. Mosca (Pisa, Italy)
SIXTH SESSION: Systemic Lupus Erythematosus and related syndromes

Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion.

Oral Communications:

OC6:1 TRANSCRIPTIONAL REGULATION OF BAFF-R, BCMA AND TACI BY MIR-873 AND MIR-1976 IN JUVENILE SLE
M.M. Fares (Cairo, Egypt)

OC6:2 THROMBOSPONDIN-1 IS ELEVATED IN THE PLASMA OF PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND IS CORRELATED WITH FREE ACTIVE TGF-B1 LEVELS, IL-1B AND IL-17A
P. Vlachoyiannopoulos (Athens, Greece)

OC6:3 HYDROXYCHLOROQUINE DOSING: DOES BY IDEAL BODY WEIGHT OR GROSS WEIGHT MAKE A DIFFERENCE?
H.S.E. Fung (Waco, Texas-Usa)

OC6:4 AVEMAR, A NEW BENZOQUINONE CONTAINING NATURAL PRODUCT IN SLE PATIENTS TREATMENT
S.G. Sukkar (Genoa, Italy)

OC6:5 ANTIPHOSPHOLIPID SYNDROME: REVIEW OF 52 CASES OF A PORTUGUESE RHEUMATOLOGY DEPARTMENT
F. Campos Costa (Coimbra, Portugal)

OC6:6 OUTCOME OF ADULT PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS AND JUVENILE IDIOPATHIC ARTHRITIS IN A SINGLE COHORT
S. Al-Mayouf (Riyadh, Saudi Arabia)

Chair – INTRODUCTION:
P. Miossec (Lyon, France)

PATIENT SESSION:

Open Questions to the Physician Nutritionist and to the Dietician

SESSIONE DEDICATA AI PAZIENTI:
Domande libere al Medico nutrizionista ed alla Dietologa

Concomitant Session

Chairs:
R. Gradaschi (Genoa, Italy), S.G. Sukkar (Genoa, Italy)
SEVENTH SESSION: Spondyloarthritis and Psoriatic Arthritis

Speakers:
8.30  Epidemiology, nutritional aspects and environmental factors  
      R. Lories (Leuven, Belgium)
8.45  The early disease: clinical features and diagnostic tools  
      I.E. Van der Horst-Bruinsma (Amsterdam, The Netherlands)
9.00  Management: from guidelines up to the last treatment issues  
      R. Ramonda (Padua, Italy)
9.15  Management: non pharmacological aspects and unmet needs  
      F. Ciccia (Palermo, Italy)

Chairs:
S. D’Angelo (Potenza - Matera, Italy), R. Lories (Leuven, Belgium)

SEVENTH SESSION: Spondyloarthritis and Psoriatic Arthritis

Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

Oral Communications:

OC7:1  METABOLIC SYNDROME, NON ALCOHOLIC FATTY LIVER DISEASE AND LIVER STIFFNESS IN PSORIATIC ARTHRITIS AND PSORIASIS PATIENTS: A CROSS-SECTIONAL STUDY  
      A. Ortolan (Padua, Italy)

OC7:2  DO NOT DO RECOMMENDATIONS IN THE MANAGEMENT OF COMORBIDITY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. GECOAX PROJECT  
      L. Carmona (Madrid, Spain)

OC7:3  EFFECT OF FOOD INTAKE AND AMBIENT PARTICULATE AIR POLLUTION ON ANKYLOSING SPONDYLITIS DISEASE ACTIVITY  
      N. Soleimanifar (Tehran, Iran)

OC7:4  BONE DENSITY IN ALGERIAN PATIENTS WITH ANKYLOSING SPONDYLITIS  
      B. Bengana (Algiers, Algeria)

OC7:5  EFFICACY AND SAFETY OF USING ETANERCEPT IN TREATMENT OF SPONDYLOARTHROPATHIES, EXPERIENCE OF MONTENEGRO  
      E. Strujic (Podgorica, Montenegro)

OC7:6  A SUSTAINABLE RELIEF OF CHRONIC LOW BACK PAIN IMMEDIATELY AFTER ONE SESSION OF LOW-LEVEL LASER ACUPUNCTURE THERAPY  
      D. Houssien (Jeddah, Saudi Arabia)

Chair – INTRODUCTION:
R. Gerli (Perugia, Italy)

SPECIAL ULTRASOUND SESSION: What about pitfalls and misinterpretations related to the nutritional status in Rheumatic Diseases?

Concomitant Session

Speakers:
8.30  Ultrasound in Rheumatology: what, why, when do we assess musculoskeletal tissues and other organs?  
      A. Iagnocco (Turin, Italy)
Saturday, April 14th 2018

8.50  Tips and tricks for pitfalls and misinterpretations related to the nutritional status in Rheumatic Diseases  
**C. Martinoli** (Genoa, Italy)

9.20  Clinical cases: Ultrasound examinations in patients with nutritional status abnormalities  
**C. Martinoli** (Genoa, Italy), **B. Ruaro** (Genoa, Italy)

Chair:  
**A. Iagnocco** (Turin, Italy)

9.40 – 10.50  Platea Maestrale Room

**EIGHTH SESSION: Osteoporosis and life style**

**Speakers:**

9.40  Epidemiology, nutritional aspects and environmental factors  
**L. Carmona** (Madrid, Spain)

9.55  The early disease: clinical features and diagnostic tools  
**L. Sinigaglia** (Milan, Italy)

10.10  Management: from guidelines up to the last treatment issues  
**M.L. Brandi** (Florence, Italy)

10.25  Management: non pharmacological aspects and unmet needs  
**J.A.P. Da Silva** (Coimbra, Portugal)

Chairs: **M.L. Brandi** (Florence, Italy), **L. Carmona** (Madrid, Spain)

9.40 – 10.50  Levante – Ponente Room

**EIGHTH SESSION: Osteoporosis and life style**

*Concomitant Session and related Oral Communications*

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

**Oral Communications:**

OC8:1  CHARACTERIZATION OF A NOVEL VITAMIN D RECEPTOR (VDR) POLYMORPHISM BY SEQUENCE-BASE TYPING  
**M.C. Padula** (Potenza, Italy)

OC8:2  ANKYLOSING SPONDYLITIS BONE: “STIFF AND BRITTLE AS A CRISTAL GOBLET”  
**S. Paolino** (Genoa, Italy)

OC8:3  VERTEBRAL BONE MINERAL DENSITY EVALUATION USING A QUANTITATIVE ULTRASOUND METHOD (ECHOLIGHT) IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS  
**R. Decianu** (Bucharest, Romania)

OC8:4  FEMORAL NECK BONE MINERAL DENSITY EVALUATION USING A QUANTITATIVE ULTRASOUND METHOD (ECHOLIGHT) IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS  
**R. Decianu** (Bucharest, Romania)

OC8:5  COMPARISON OF THE EFFECT OF DENOSUMAB ON BONE MINERAL DENSITY OF LUMBAR SPINE AND FEMORAL NECK IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS, WHEN ADMINISTERED AS FIRST-LINE THERAPY OR AFTER BISPHOSPHONATE  
**E. Mole** (Kifisia, Greece)

OC8:6  CASE REPORT - CALCIUM INTAKE IN RHEUMATIC DISEASES: “EST MODUS IN REBUS”  
**S. Paolino** (Genoa, Italy)

Chair – **INTRODUCTION:**  
**R. Ionescu** (Bucharest, Romania)
Saturday, April 14th 2018

09.40 – 10.50 Libeccio Room NO CME ACTIVITY

PATIENT SESSION: The cold hand: from symptom to diagnosis
SESSIONE DEDICATA AI PAZIENTI: La mano fredda: dal sintomo alla diagnosi

Concomitant Session

Speakers:

The cold hand: the symptom
F. Ingegnoli (Milan, Italy)
The cold hand: the diagnosis
V. Smith (Ghent, Belgium)

Chairs:
V. Smith (Ghent, Belgium), F. Ingegnoli (Milan, Italy)

10.50 – 11.20 Poster and Exhibition Area

Coffee break

11.20 – 12.30 Platea Maestrale Room

NINTH SESSION: Sjögren syndrome today

Speakers:

11.20 New nutritional aspects as possible risk factors: the role of salt
Tbd

11.35 The early disease: clinical features and diagnostic tools
A. Tzioufas (Athens, Greece)

11.50 Management: from guidelines up to the last treatment issues
X. Mariette (Paris, France)

12.10 Management: non pharmacological aspects and unmet needs
L. Quartuccio (Udine, Italy)

Chairs:
X. Mariette (Paris, France), A. Tzioufas (Athens, Greece)

11.20 – 12.30 Levante – Ponente Room

NINTH SESSION: Sjögren syndrome today
Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

Oral Communications:

OC9:1 ERD5 FUNCTION IS INVOLVED IN INFLAMMATORY MANIFESTATIONS OF SJÖGREN’S SYNDROME IN THE SALIVARY GLAND
A. Tzioufas (Athens, Greece)

OC9:2 LOW MIR200B-5P LEVELS IN MINOR SALIVARY GLANDS ASSOCIATE WITH LYMPHOMA DEVELOPMENT IN PATIENTS WITH SJÖGREN’S SYNDROME (SS)
A. Tzioufas (Athens, Greece)

OC9:3 SCORING SYSTEMS IN ULTRASOUND OF SALIVARY GLANDS IN SJÖGREN SYNDROME A VIEW OVER TIME
V. Iorgoveanu (Bucharest, Romania)

OC9:4 ULTRASONOGRAPHIC SCORING OF THE MAJOR SALIVARY GLANDS: IS THERE A RELATIONSHIP WITH DISEASE ACTIVITY AND FUNCTIONAL STATUS OF GLANDS
Y. Şahinkaya (Istanbul, Turkey)

OC9:5 SJÖGREN SYNDROME: EVALUATION OF THE DISEASE ACTIVITY USING THE ESSDAI IN 70 PATIENTS
J. Dinis De Freitas (Coimbra, Portugal)
Chair – INTRODUCTION:
N. Damjanov (Belgrade, Serbia)

11.20 – 12.30 Libeccio Room **NO CME ACTIVITY**
**PATIENT SESSION: Balneotherapy explained**
SESSIONE DEDICATA AI PAZIENTI: La balneoterapia spiegata: Come usarla?
Concomitant Session
Speakers:
**T. Bender** (Budapest, Hungary)
**A. Fioravanti** (Siena, Italy)
Chairs:
**L. Di Matteo** (Pescara, Italy), **Z. Szekanecz** (Debrecen, Hungary)

12.30 – 12:45 Platea Maestrale Room
**CLOSING REMARKS**

Further variations to the Scientific Program should be expected before the Congress
### Friday, April 13\(^{\text{th}}\) 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.20 – 11.50</td>
<td>Platea Maestrale Room</td>
<td><strong>Concomitants Industry SATELLITE LECTURE</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>New targets in RA treatment: the case of Janus Kinases inhibition</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Speaker:</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>R. Caporali</strong> <em>(Pavia, Italy)</em></td>
</tr>
<tr>
<td>11.20 – 11.50</td>
<td>Levante – Ponente Room</td>
<td><strong>Concomitants Industry SATELLITE LECTURE</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Gout, a disease of our days: 2018 therapeutical innovations</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Speaker:</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>L. Punzi</strong> <em>(Padua, Italy)</em></td>
</tr>
<tr>
<td>11.50 – 12.50</td>
<td>Platea Maestrale Room</td>
<td><strong>Concomitants Industry SATELLITE SYMPOSIUM</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>PAH_CTD: new insights</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Speakers:</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>M. Matucci-Cerinic</strong> <em>(Florence, Italy)</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>ESC/ERS PH Guidelines and treatment strategies</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>M. Palazzini</strong> <em>(Bologna, Italy)</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>The GRIPHON Study: CTD subgroup analysis</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>C. Denton</strong> <em>(London, UK)</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Chairs:</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>M. Cutolo</strong> <em>(Genoa, Italy), V. Smith</em>* <em>(Ghent, Belgium)</em></td>
</tr>
<tr>
<td>11.50 – 12.20</td>
<td>Levante-Ponente Room</td>
<td><strong>Concomitants Industry SATELLITE SYMPOSIUM</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Patient profiling for therapy with Apremilast in psoriaritic arthritis</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Speaker:</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>A. Marchesoni</strong> <em>(Milan, Italy)</em></td>
</tr>
<tr>
<td>12.20 – 12.50</td>
<td>Levante-Ponente Room</td>
<td><strong>Concomitants Industry SATELLITE SYMPOSIUM</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>IL6: the key of rheumatoid arthritis</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Speaker:</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>S. Bugatti</strong> <em>(Pavia, Italy)</em></td>
</tr>
<tr>
<td>16.40 – 17.10</td>
<td>Exhibition Booth</td>
<td><strong>MEET THE EXPERT</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Meet the Expert organizzato con il contributo educazionale di Grünenthal</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Lesinurad - The long awaited innovation in Gout</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>P. Richette</em>* <em>(Paris, France)</em></td>
</tr>
</tbody>
</table>
Friday, April 13th 2018
12.50 – 14:00  Poster Area

**Poster Tour 1:** Autoinflammatory and Rare Connective Tissue Diseases

**Poster Tour 2:** Gout and arthritis in dismetabolic conditions

**Poster Tour 3:** Osteoarthritis: Thermal and pharmacological management

**Poster Tour 4:** Osteoporosis/Osteomalacia and malabsorption

**Poster Tour 5:** Psoriatic arthritis / spondyloarthritis

**Poster Tour 6A-B:** Rheumatoid arthritis

**Poster Tour 7:** Sjogren Syndrome and endocrine rheumatic disorders

**Poster Tour 8A-B:** Systemic lupus erythematosus / Antiphospholipid syndrome

**Poster Tour 9A-B:** Systemic Sclerosis and Raynaud phenomenon

**Poster Tour 1:** Autoinflammatory and Rare Connective Tissue Diseases

*Chair: L. Cantarini (Siena, Italy)*

**PT1:001**
IDIOPATHIC INFLAMMATORY MYOPATHIES: CLINICAL CHARACTERISTICS, SURVIVAL AND POOR PROGNOSTIC FACTORS OF 110 PATIENTS FROM TURKEY
E. Oguz, M. Erdugan, B. Artim Esen, A. Gul, L. Ocal, M. Inanc (Istanbul, Turkey)

**PT1:002**
PARADOXICAL MONOARTHRITIS IN THE CASE RECEIVING ADALIMUMAB TREATMENT DUE TO HIDRADENITIS SUPPURATIVE
S.E. Esmen, S. Arslan, I. Guney (Konya, Turkey)

**PT1:003**
DERMATOMYOSITIS ASSOCIATED WITH PAPILLARY THYROID CANCER: A CASE REPORT AND REVIEW OF LITERATURE
S. Ugurlu, U. Yilmaz, H. Ozdogan (Istanbul, Turkey)

**PT1:004**
SARCIOIDOSIS FOLLOWING MYCOPLASMA PNEUMONIAE INFECTION
I. Sofianos, G. Spiliotis, P. Tzanis, I. Mirokofitakis (Voula, Greece)

**PT1:005**
A DIAGNOSTIC AND THERAPEUTIC CHALLENGE - BEHCET’S DISEASE
A. Savulescu, L. Ciobicu, A. Dumitru, I. Sirbu, L. Panturu, D. Anghel (Bucharest, Romania)

**PT1:006**
ARTHRITIS – THE SUBSTRATE OF A RARE DERMATOLOGIC DISEASE
C. Radu, L. Grosea (Bucharest, Romania)

**PT1:007**
SERUM VISFATIN LEVELS IN BEHCET’S DISEASE PATIENTS
Z. Ozbalkan-Aslar, M. Enecik, G. Keskin, Y. Araaslan (Ankara, Turkey)

**PT1:008**
LYMPHOMA CASE IMITATING TAKAYASU ARTERITIS
G. Kimyon, R. Erdem, E. Micoogullari, R. Mercan (Hatay, Turkey)

**PT1:009**
TAKAYASU’S ARTERITIS: EXPERIENCE OF A SINGLE TERTIARY CENTER

**PT1:010**
A GOOD MIMIC: PMR - IS PMR THE ACCURATE DIAGNOSIS?: A SINGLE-CENTER STUDY
SYSTEMIC SARCoidOSIS ASSOCIATED WITH VIRAL HEPATiTIS C: FORTUITOUS ASSOCIATION OR A CAUSAL EFFECT?
M. Kechida, R. Mesfar, W.B. Mansour, M. Hafsa, S. Hammami, I. Khochtali (Monastir, Tunisia)

TOCILIZUMAB AS POTENTIAL FIRST OPTION BIOLOGIC THERAPY IN SNITZLER’S SYNDROME
E.S. Daia-Ilieșcu, C. Buzatu, R. Ionescu (Bucharest, Romania)

THE IMPACT OF PROLONGED CORTICOTHERAPY ON DAMAGE PROGRESSION IN PATIENTS WITH BEHÇET’S DISEASE
E.S. Daia-Ilieșcu, C. G. Buzatu, I. Saulescu, A. Borangiu, L. Groseanu, V. Bojinca, F. Berghea, D. Predeteanu, R. Ionescu, D. Opris-Belinski (Bucharest, Romania)

TERTIARY SYPHILIS IN A PATIENT WITH TRAPS UNDER CANAKINUMAB TREATMENT: CASE REPORT
D. Temiz Karadag, A. Yazici, A. Cefle (Kocaeli, Turkey)

ADULT STILL’S DISEASE – SERIES OF CLINICAL CASES IN A ROMANIAN REFERENCE CENTER

Poster Tour 2: Gout and arthritis in dismetabolic conditions
Chair: L. Punzi (Padua, Italy)

MUSCULOSKELETAL ULTRASOUND ABNORMALITIES IN PATIENTS ON DIALYSIS
R. Decianu, M. Bojinca, C. Capusa, A. Zugravu, V.C. Bojinca (Bucharest, Romania)

EFFECT OF LOSARTAN IN LOWERING THE LEVEL OF URIC ACID IN PLASMA IN ALBANIAN PATIENTS WITH HYPERURICEMIA AND HYPERTENSION
M. Jordhani, D. Ruci, V. Duraj (Tirana, Albania)

PULMONARY ADENOCARCINOMA PRESENTED WITH ARTHRITIS
S.E. Esmen, H. Erdogan, E. Kurtipek (Konya, Turkey)

Poster Tour 3: Osteoarthritis: Thermal and pharmacological management
Chair: T. Bender (Budapest, Hungary)

PATIENT’S EXPERIENCE OF ALTERED BODY PERCEPTION IN MUSCULOSKELETAL AND RHEUMATIC CONDITIONS
A. Viceconti, D. Luzzi, E. Camerone, M. Testa (Savona, Italy)

A LOW FERMENTABLE OLIGO-DI-MONOSACCHARIDES AND POLYOLS DIET IMPROVES SYMPTOMS WITHOUT AFFECTING BODY COMPOSITION AND EXTRACELLULAR BODY WATER IN FIBROMYALGIC PATIENTS WITH IRRITABLE BOWEL SYNDROME
A. Rossi, M. Bellini, A. Ricciardi, S. Marchi, S. Talarico, M. Mosca, L. Bazzichi (Pisa, Italy)

CONTROL AND MANIPULATION OF CONTEXTUAL FACTORS IN MUSCULOSKELETAL PAIN MANAGEMENT. A VALID OPPORTUNITY TO ENHANCE THE EFFECTIVENESS OF THE SPECIFIC THERAPY
G. Rossettini (1), E. Carlino (2), A. Palese (3), M. Testa (1) (1) Genoa (Italy), (2) Turin (Italy), (3) Udine (Italy)

EFFICACY AND SAFETY OF INTRA-ARTICULAR CORTICOSTEROID ULTRASOUND-GUIDED INJECTION IN EROSIVe HAND OSTEOARTHRITIS

COULD HYBRID HYALURONIC ACID REPRESENT A VALID APPROACH TO TREAT RIZOARTHRITIS? A RETROSPECTIVE COMPARATIVE STUDY
S. Tenti, S. Cheleschi, S. Giannotti, M. Galeazzi, N.A. Giordano, A. Fioravanti (Siena, Italy)
PT3:024 PAIN IN KNEE: MORE THAN JUST WEAR AND TEAR DUE TO OSTEOARTHRITIS
M. Parvu, G. Novac, A. Nistor, I. Scheip, S. Voidazan (Tg Mures, Romania)

PT3:025 INTRA-ARTICULAR HYALURONIC ACID FOR KNEE OSTEOARTHRITIS: TWO YEARS EFFICACY OF A QUARTERLY REGIMEN
F. Galluccio, M. Capassoni, M. Matucci Cerin (Florence, Italy)

PT3:026 THE EFFECTIVENESS OF SAFFRON PILL IN TREATMENT OF OSTEOARTHRITIST: A RANDOMIZED, DOUBLE-BLIND CONTROLLED TRIAL
M. Firoozabadi (1), M. Aghei (1), S.Z. Mirteizi (2), G.R. Roshandel (3), N. Abdolahi (1)
(1) Golestan (Iran), (2) Razavi Khorasan (Iran), (3) Gorgan (Iran)

PT3:027 BALNEOTHERAPY IN KNEE OSTEOARTHRITIS: A COST/EFFECTIVENESS ANALYSIS ALONGSIDE AN ITALIAN RANDOMIZED CONTROLLED CLINICAL TRIAL
A. Fioravanti (1), O. Ciani (2), S. Tenti (3), C. Giannitti (1), M. Meregaglia (2), M. Galeazzi (1)
(1) Siena (Italy), (2) Milano (Italy), (3) Siena (Italy)

Poster Tour 4: Osteoporosis/Osteomalacia and malabsorption
Chair: S. Sokolovic (Sarajevo, Bosnia and Herzegovina)

PT4:028 VITAMIN D DEFICIENCY IN THE ACUTE CARE UNIT. IS IT RELATED TO SURVIVAL?
I. Kostoglou-Athanassiou (1), E. Pantazi (1), I. Mavropoulos (1), O. Skioti (1), D. Kousouris (1),
S. Kontogiannis (1), P. Athanassiou (2)
(1) Athens (Greece), (2) Thessaloniki (Greece)

PT4:029 VITAMIN D DEFICIENCY AND OSTEOMALACIA IN ACUTELY ILL PATIENTS AFTER SURGICAL TREATMENT FOR COLON CANCER
P. Athanassiou (1), L. Athanassiou (2), P. Potamousi (2), R. Alevizou (2), M. Digalakis (2), I. Kostoglou-Athanassiou (2)
(1) Thessaloniki (Greece), (2) Athens (Greece)

PT4:030 EFFECTIVENESS OF DENOSUMAB IN ADJUSMENT OF OSTEOPOROSIS TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
R. Yatsyshyn, O. Shtefiuk, I. Popadynets, G. Kuryliv, I. Stroika (Ivano-Frankivsk, Ukraine)

PT4:031 EVALUATION OF EFFECTS OF ADAPTED PHYSICAL ACTIVITY PROGRAM ON FUNCTIONAL ORGANIC INDEXES AND BMD IN OSTEOPOROTIC PATIENTS TREATED WITH DENOSUMAB
A. Romeo, C. Baiano (Syracuse, Italy)

PT4:032 BREAST CANCER AND SKELETAL HEALTH: EVALUATION OF BONE MINERAL DENSITY AND FRACTURE RISK
S. Paolino, E. Gotelli, V. Tomatis, R. Murialdo, L. Tixi, R. Gonella, A. Ballestrero, M. Cutolo (Genoa, Italy)

PT4:033 THE 3-YEAR EFFICACY OF ZOLEDRONIC ACID ON BONE MINERAL DENSITY OF LUMBAR SPINE AND FEMORAL NECK IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
E. Mole, K. Zoupidou, A. Alexoudis, D. Moshou, G. Prelorentzos, S. Gazi (Kifisia, Greece)

PT4:034 TENDENCIES OF BONE MINERAL DENSITY IN YOUNG ADULTS AND THE INFLUENCE OF DIET AND OTHER LIFESTYLE HABITS
I. Badea (Bucharest, Romania)

Poster Tour 5: Psoriatic arthritis / spondyloarthritis
Chair: R. Ramonda (Padua, Italy)

PT5:035 THE PREVALENCE AND COMORBIDITIES ASSOCIATED WITH PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS: AN OBSERVATIONAL COHORT STUDY
A. Abdalla (1), M. Abd El Haleem (2)
(1) Aswan (Egypt), (2) Benha (Egypt)

PT5:036 ASSOCIATION BETWEEN LIVER STEATOSIS, METABOLIC PROFILE AND RHEUMATOLOGIC DISEASES: A SINGLE CENTER STUDY
C. Bruno, R. Grembiale, L. Abenavoli, S. Naty (Catanzaro, Italy)
OBESITY AND RESPONSE TO TNF INHIBITORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS – DATA FROM A ROMANIAN COHORT
C. Ancuta, C. Pomirleanu, R. Paiu, E. Ancuta, C. Iordache, I. Esanu, R. Chirieac (Iasi, Romania)

PREVALENCE OF COMORBIDITIES IN PSORIATIC ARTHRITIS: A CROSS-SECTIONAL STUDY

HYPERURICEMIA IN PSORIATIC ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS
T.E. Gudu, A. Peltea, A. Balanescu, V. Bojinca, D. Opris-Belinski, D. Predeteanu, R. Ionescu (Bucharest, Romania)

PARADOXICAL INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH SPONDYLOARTHROPATHIES TREATED WITH ANTI-TNF AGENTS
C. Ancuta, C. Pomirleanu, R. Paiu, E. Ancuta, R. Chirieac (Iasi, Romania)

METABOLIC SYNDROME AND ANKYLOSING SPONDYLITIS IN ALGERIAN PEOPLE
R. Benaziez-Boutaleb, O. Cheikh, M. Berkache, M. A. Ifticene, C. Dahou-Makhloufi (Algiers, Algeria)

HYPERURICEMIA IN PSORIATIC ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS
T.E. Gudu, A. Peltea, A. Balanescu, V. Bojinca, D. Opris-Belinski, D. Predeteanu, R. Ionescu (Bucharest, Romania)

METABOLIC SYNDROME AND ANKYLOSING SPONDYLITIS IN ALGERIAN PEOPLE
R. Benaziez-Boutaleb, O. Cheikh, M. Berkache, M. A. Ifticene, C. Dahou-Makhloufi (Algiers, Algeria)

PARADOXICAL INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH SPONDYLOARTHROPATHIES TREATED WITH ANTI-TNF AGENTS
C. Ancuta, C. Pomirleanu, R. Paiu, E. Ancuta, R. Chirieac (Iasi, Romania)

ASAS HEALTH INDEX AND ENVIRONMENTAL FACTORS (ASAS HI/EF) IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND CONCOMITANT FIBROMYALGIA
I. Shapoval, M. Stanislavchuk, K. Zaichko (Vinnytsia, Ukraine)

DNA METHYLOME AND SERUM PROTEOME ANALYSES IDENTIFY NEW BIOMARKERS OF PSORIASIS AND PSORIATIC ARTHRITIS IN MONOZYGOTIC TWINS
(1) Rozzano (Italy), (2) Milan (Italy)

PROTEIN LEVELS AND AUTOANTIBODIES AGAINST LL37 AND IFI16 NUCLEIC ACID SENSORS IN PSORIATIC ARTHRITIS
M. Meroni (1), N. Isailovic (1), M. De Santis (1), A. Ceribelli (1), E. Generali (1), L. Altamore (2), G. Sabatino (2), P. Rovero (2), A.M. Papini (2), V. Caneparo (3), S. Landolfo (3), M. Gariglio (4), M. De Andrea (4), C. Selmi (1,5)
(1) Rozzano (Italy), (2) Florence (Italy), (3) Turin (Italy), (4) Novara (Italy), (5) Milan (Italy)

THE INFLUENCE OF SMOKING ON RESPONSE TO ANTI TNF THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS
D. Anghel, C. Jurcut, A. Anghel, M.M Negru, A.E. Savulescu, L. Panturu (Bucharest, Romania)

FACTORS ASSOCIATED WITH STOPPING BIOLOGICAL TREATMENT IN PATIENTS WITH ANKYLOSING SPONDYLITIS
G. Iftimie, C. Buta, L. Groseanu, R. Ionescu, D. Opris-Belinski (Bucharest, Romania)

ULTRASONOGRAPHIC CHANGES OF ASYMPTOMATIC ANTERIOR CHEST WALL JOINTS IN ANKYLOSING SPONDYLITIS AND THEIR RELATION TO CHEST EXPANSION
F. Hassan (1), M. Mortada (1), A. Bakry (1), A. Elsammak (1)
(1) Zagazig (Egypt)

GLOBAL HEALTH ASSESSMENT BY RHEUMATOLOGIST AND BY PATIENT IN PSORIATIC ARTHRITIS, RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS
F. Grubisic, H. Skala Kavangh, I. Doko, S. Grazio (Zagreg, Croatia)

TWO-YEARS SURVIVAL OF USTEKINUMAB IN PSORIATIC ARTHRITIS PATIENTS
R.D. González Benítez, J. Janta, B. Serrano Benavente, J. C. Nieto Gonzalez, M. Correyero, C.M. Gonzalez Fernandez (Madrid, Spain)

PROTEIN LEVELS AND AUTOANTIBODIES AGAINST LL37 AND IFI16 NUCLEIC ACID SENSORS IN PSORIATIC ARTHRITIS
M. Meroni (1), N. Isailovic (1), M. De Santis (1), A. Ceribelli (1), E. Generali (1), L. Altamore (2), G. Sabatino (2), P. Rovero (2), A.M. Papini (2), V. Caneparo (3), S. Landolfo (3), M. Gariglio (4), M. De Andrea (4), C. Selmi (1,5)
(1) Rozzano (Italy), (2) Florence (Italy), (3) Turin (Italy), (4) Novara (Italy), (5) Milan (Italy)

THE ASSESSMENT OF THE RELATION BETWEEN SERUM URIC ACID LEVEL AND DISEASE ACTIVITY IN ANKYLOSING SPONDYLITIS
I.H. Dursun, F. Cosan, B. Yilmazer, A. Cefle (Kocaeli, Turkey)
PT5:052 OBESITY INTERACTS WITH RESPONSE AND INCREASES THE RISK OF HYPERTRANSAMINEMINA IN PSORIATIC ARTHRITIS
L. Carmona (1), E. Galindez (2)
(1) Madrid (Spain) (2) Bilbao (Spain)

Poster Tour 6A: Rheumatoid arthritis
Chair: A. Alunno (Perugia, Italy)

PT6A:053 RITUXIMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN A PATIENT WITH COMORBIDITY – CHONDROSARCOMA/OSTEOSARCOMA OF THE CAVERNOUS SINUS
M. Baresic, L Simetic, D Herceg, B Anic (Zagreb, Croatia)

PT6A:054 PERIPHERAL BLOOD B-CELL SUBSETS IN PATIENTS WITH VERY EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS
A. Avdeeva, A. Aleksankin, T. Popkova, E. Suponitskaya, E. Nasonov (Moscow, Russia)

PT6A:055 IS IT POSSIBLE TO REPLACE THE RADIOLOGICAL ASSESSMENT OF DESTRUCTIVE CHANGES IN RHEUMATOID ARTHRITIS (RA) BY ULTRASOUND (US) EXAMINATION?
O. Alexeeva, A. Smirnov, A. Volkov, E. Nasonov (Moscow, Russia)

PT6A:056 EDUCATING PEOPLE WITH RMDS TO FOLLOW A CORRECT DIET: AN INNOVATIVE 3 STEPS PROJECT
U.G. Viora, S. Severoni, S. Tonolo (Rome, Italy)

PT6A:057 FOLIC ACID SUPPLEMENTATION REDUCES METHOTREXATE EFFICACY AND DELAY CLINICAL IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS
A. Sulli, S. Paolino, C. Pizzorni, E. Alessandri, M. Patane’, M. Ghio, M. Cutolo (Genoa, Italy)

PT6A:058 CLINICAL AND ECONOMIC VALUE OF SERUM AUTOANTIBODIES MULTI-TESTING IN RHEUMATOID ARTHRITIS IN THE MEDITERRANEAN AREA
B. Mascialino (1), S. Swiniarski (2), I. Gehring (2), M. Poorafshar (1)
(1) Uppsala (Sweden), (2) Freiburg (Germany)

PT6A:059 CAN DIET MODIFY RISK AND COURSE OF INFLAMMATION AND MALIGNANCY?
E. Kucharz (Katowice, Poland)

PT6A:060 TRADITIONAL TYPE 2 DIABETES RISK FACTORS AND INSULIN RESISTANCE IN PATIENTS WITH RHEUMATOID ARTHRITIS
L. Kondrateva, T. Popkova (Moscow, Russia)

PT6A:061 THE EFFECT OF TOCILIZUMAB THERAPY ON THE BODY MASS INDEX, WAIST AND HIP CIRCUMFERENCE, LIPIDS PROFILES IN PATIENTS WITH RHEUMATOID ARTHRITIS
E. Gerasimova, T. Popkova, A. Martinova, E. Zhilyaev, G. Lukina (Moscow, Russia)

PT6A:062 SMOKING AND RHEUMATOID ARTHRITIS
D. Dusa, M. Suta (Constanta, Romania)

PT6A:063 A PATIENT PRESENTING WITH JAW PAIN. DIAGNOSIS, TREATMENT AND REVIEW OF THE LITERATURE
C. Christodoulou (Larnaca – Nicosia, Cyprus)

PT6A:064 THE INFLUENCE OF ABATACEPT ON BIOMARKERS LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS

PT6A:065 THE INFLUENCE OF SMOKING ON CLINICAL RESPONSE TO ETANERCEPT THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
S. Zivojinovic, M. Bukilica, N. Damjanov (Belgrade, Serbia)

PT6A:066 SECONDARY SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS
R. Yatsyshyn, I. Stoika (Ivano-Frankivsk, Ukraine)
Diet in Children with IJA: An Innovative 4 Steps Project to Overcome Cultural Barriers
U.G. Viora, G. Mascarino, S. Tonolo (Rome, Italy)

27-Year-Old Female with Polyarthritis, Dryness Syndrome and Acute Loss of Visual Acuity
P. Tzanis, I. Sofianos, G. Spiliotis, I. Myriokefalitakis (Voula, Greece)

Poster Tour 6B: Rheumatoid Arthritis
Chair: M. Cimmino (Genoa, Italy)

Rheumatoid Arthritis Patient with Mass on the Anterior Chest Wall
Ö. Soysal Gündüz, G. Gunduz, D. Demir (Manisa, Turkey)

A Structured Protocol for the Evaluation of Cardio-Vascular Risk in Arthritis Patients
F. Sivera, N. Alberola, G. Albert, C. Fernandez-Carballido, R. Martin, T. Pedraz (Elda, Spain)

Effects of Mediterranean Diet and Physical Therapy in Early Stages of Oligoarticular Juvenile Idiopathic Arthritis
L M Alloia, C Alloia (Iasi, Romania)

Construct Validity, Reproducibility and Feasibility of the Pro-Thermometer-5ITEM (5T-PROS) in the Evaluation of the Health Status in Patients with Rheumatoid Arthritis, Spondyloarthritis and Fibromyalgia
F. Salaffi, S. Farah, M. Di Carlo, M. Carotti (Ancona, Italy)

Construct Validity and Interpretability of the QuickDash in the Assessment of Rheumatoid Arthritis Hand Disability
F. Salaffi, S. Farah, M. Di Carlo, M. Carotti (Ancona, Italy)

Evolution of Pain in Rheumatoid Arthritis Treated with Anti-Interleukin 6
N. Bidi, N. Saidi, R. Benaziez, N. Zehraoui, M.A. Itticene, F. Mechid, C. Dahou-Makhloufi (Algiers, Algeria)

Patients' Satisfaction with Health Care Provided in an Outpatient Clinic for Rheumatology: Results of a Questionnaire Study of Specific Aspects of Care
D. Cubelic (1), M. Reihl (2), M. Mayer (1), B. Anic (1)
(1) Zagreb (Croatia), (2) Vukovar (Croatia)

Predictive Factors of Evolution of Early Inflammatory Arthritis to Rheumatoid Arthritis
F. Rahal, R Chetouane, S Haid, N Brahimi, A Ladjouze-Rezig, F Hanni (Algiers, Algeria)

Ultrasonographic Findings of Hip Joints in Patients with Rheumatoid Arthritis
S. Prodanovic, G. Radunovic, N. Damjanov (Belgrade, Serbia)

Ultrasonographic Findings of Hip Joints in RA Patients
S. Prodanovic, G. Radunovic, N. Damjanov (Belgrade, Serbia)

Rituximab: Comparison Clinical and Anti-Destructive Effects and B-Cell Count in Rheumatoid Arthritis Patients.
A. Pivanova, G. Lukina, Y. Sigidin, A. Smirnov, S. Glukhova, A. Kuznetsova, E. Nasonov (Moscow, Russia)

Effect of a Dynamic Exercise Program in Combination with a Mediterranean Diet in Weight and Handgrip Strength in Women with Rheumatoid Arthritis

Rheumatoid Arthritis: Frequency and Influence of Tobacco and Body Mass Index (BMI) in the Activity of the Disease
E. Mussano, L. Onetti, I. Cadile, M. Werner, M.V. Gazzoni, M.C. Taboada, M.I. Stancich, R. Jurado (Cordoba, Argentina)
PERIODONTITIS IN EARLY RHEUMATOID ARTHRITIS: CASE-CONTROL STUDY
F. Mechid, C. Dahou, M. Meddad, S. Salah, S. Merad (Algiers, Algeria)

CONTRIBUTION OF VITAMIN D RECEPTOR FOKI GENE POLYMORPHISM ON DISEASE SEVERITY AND LONG TERM DISEASE OUTCOME IN JUVENILE IDIOPATHIC ARTHRITIS (JIA)
D. Lazarević (1), J. Vojinović (1), G. Susic (2), J. Basic (1), J. Milenković (1)
(1) Niš (Serbia), (2) Belgrade (Serbia)

IS PROTEIN C REACTIVE RELATED TO METABOLIC SYNDROME IN RHEUMATOID ARTHRITIS?
M. Kechida (1), N. Lorenzo Vilalba (2), R. Mesfar (1), Y. Alvarado Funes (2), R. Klii (1), S. Hammami (1), I. Khochtali (1)
(1) Monastir (Tunisia), (2) Liège (Belgium)

THE EFFICACY AND SAFETY OF METHOTREXATE IN A DOSE 25 MG PER WEEK AND MORE IN PATIENTS WITH RHEUMATOID ARTHRITIS.
G. Gridneva, Y. Muraviev (Moscow, Russia)

Poster Tour 6C: Rheumatoid arthritis

Chair:
A. Iagnocco (Turin, Italy)

IMPAIRED WOUND HEALING DUE TO LEFLUNOMIDE USE IN PATIENTS WITH RHEUMATOID ARTHRITIS
V. Gerdan (Izmir, Turkey)

THE EFFECT OF GENDER ON ANEMIA FREQUENCY IN RHEUMATOID ARTHRITIS
S.E. Esmen, A. Tekinalp (Konya, Turkey)

THE RELATIONSHIP OF ANEMIA FREQUENCY AND DISEASE ACTIVITY IN THE PATIENTS WITH RHEUMATOID ARTHRITIS
S.E. Esmen, A. Tekinalp (Konya, Turkey)

KIR GENE DISTRIBUTION IN TURKISH PATIENTS WITH RHEUMATOID ARTHRITIS
E. Erken, F. Kocabas, O. Ozturk, S. Dinkci, N. Yilmaz (Adana, Turkey)

FACTORS CONTRIBUTING TO DISABILITY IN RHEUMATOID ARTHRITIS PATIENTS: AN EGYPTIAN MULTICENTER STUDY
M. Eissa (1), M. Hammad (2), G. Dawa (2)
(1) Cairo (Egypt), (2) Zagazig (Egypt)

NEW DYNAMOMETRIC PARAMETERS IN EVALUATION OF HAND FUNCTION IN RHEUMATOID ARTHRITIS BASED ON DYNAMIC MEASUREMENTS—A PILOT EVALUATION STUDY
I. Doko, A. Dubravic , I. Michieli, B. Medved Rogina, S.Grazio (Zagreb, Croatia)

PYODERMA GANGRENSUM: A PARADOXICAL SIDE EFFECT IN A RHEUMATOID ARTHRITIS PATIENT TREATED WITH GOLIMUMAB
T. Dimitroulas, D.M. Manoli, A. Skalkou, V. Douros, K. Petidis, S. Vakirlis, A. Pyrpasopoulou (Thessaloniki, Greece)

METHOTREXATE INTOXICATION: BEYOND THE ADVERSE EVENTS
E. Dalkilic, B.N. Coskun, B. Yagiz, S. Ermutur, A.N. Tufan, Y. Pehlivan (Bursa, Turkey)

ORAL STATUS IN RHEUMATOID ARTHRITIS PATIENTS: RESULTS OF AN ALGERIAN STUDY
C. Dahou-Makhloffi, F. Mechid, R. Benaziez, M. Meddad, S.S. Salah, N. Zehraoui, S. Merad (Algiers, Algeria)

LOW RHEUMATOID ARTHRITIS PREVALENCE IN ALGERIA: A MEDITERRANEAN SINGULARITY?
C. Dahou-Makhloffi, F. Mechid, R. Benaziez, N. Zehraoui , D. Matari, H.T. Haddad, M. Oussaid, M. Achek (Algiers, Algeria)

IMMUNOCORRECTIVE THERAPY IN THE COMPLEX TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
I. Chyzheuskaya, L. Belyaeva, L. Zaitseva, H. Khrustaleva, H. Kolupaeva (Minsk, Belarus)
Poster Tour 7: Sjogren Syndrome and endocrine rheumatic disorders

Chair: G.D. Kitas (Paris, France)


PT7:105 RENAL INVOLVEMENT IN PRIMARY SJOGREN SYNDROME-A CASE REPORT L. Brites, J. Freitas, M. Luis, J. Rovisco, M. Santiago, C. Duarte, A. Malcata, F. Costa (Coimbra, Portugal)

PT7:106 ANCA-ASSOCIATED VASCULITIS IN A PATIENT WITH PRIMARY SJOGREN SYNDROME P. Athanassiou, D. Pantelidis, C. Gerodimos (Thessaloniki, Greece)

PT7:107 SECONDARY SJOGREN SYNDROME: CLINICAL FEATURES AND PREDICTIVE FACTORS M. Kechida (1), N. Lorenzo Vilalba (2), A. Alaya (1), R. Mesfar (1), R. Kili (1), S. Hammami (1), I. Khochtali (1)
(1) Monastir (Tunisia), (2) Liege (Belgium)

PT7:108 VITAMIN D STATUS IN A LUCANIAN COHORT OF ANTI-DFS70/LEDGF POSITIVE ADULT SUBJECTS T. Carbone, G. Tramontano, M. Gili, M.C. Padula, A. Padula, V. Pafundi, S. D'angelo (Potenza, Italy)

(1) Monastir (Tunisia), (2) Liege (Belgium)

Poster Tour 8A: Systemic lupus erythematosus / Antiphospholipid syndrome

Chair: A. Doria (Padua, Italy)

GANGRENE IN SYSTEMIC LUPUS ERYTHEMATOSUS: ABOUT TWO CASES
N. Blidi, N. Zehraoui, R. Atamane, C. Dahou (Algeria)

VITAMIN D DEFICIENCY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND RELATIONSHIP WITH DISEASE ACTIVITY
I. Athanassiou (1), I. Kostoglou-Athanassiou (1), C. Katsavouni (2), A. Tzanavari (2), A. Kotel (2), C. Mavragani (1), M. Koutsilieris (1), P. Athanassiou (2) (1) Athens (Greece), (2) Thessaloniki (Greece)

NAILFOLD CAPILLAROSCOPY IN SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL
M. Cutolo (1), K. Melsens (2), S. Wijnant (2), F. I. Engegnoli (3), K. Thevissen (2), F. De Keyser (2), S. Decuman (2), U. Müller-Ladner (4), Y. Piette (2), V. Riccieri (5), N. Ughi (3), E. Vandecasteele (2), A. Vanhaecke (2), V. Smith (2) (1) Genoa (Italy), (2) Ghent (Belgium), (3) Milan (Italy), (4) Bad-Nauheim (Germany), (5) Rome (Italy)

EVALUATION OF PERIPHERAL BLOOD PERFUSION IN SYSTEMIC LUPUS ERYTHEMATOSUS AND PRIMARY RAYNAUD'S PHENOMENON PATIENTS.
B. Ruaro (1), A. Sulli (1), C. Pizzorni (1), S. Paolino (1), V. Smith (2), M. Pendolino (1), M. Cutolo (1) (1) Genoa (Italy), (2) Ghent (Belgium)

EXPRESSION OF TNF-A AND IL-6 IN PATIENTS WITH UNTREATED SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RELATIONSHIP WITH DISEASE ACTIVITY
T. Panafidina, T. Popkova, E. Alexandrova (Moscow, Russia)

INCREASED CARDIOVASCULAR AND METABOLIC COMORBIDITIES IN ROMANIAN LUPUS PATIENTS
D. Opris-Belinski, A. Balalanescu, C. Branescu, D. Predeteanu, V. Bojinca, I. Saulescu, L. Groseanu, C. Nicolae, C. Constantinescu, R. Ionescu (Bucharest, Romania)

CLINICAL MANIFESTATIONS AND LABORATORY MARKERS THAT IMPACT LONG TERM DAMAGE IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME

THE IMPACT OF THE PLACE OF RESIDENCE ON SYSTEMIC LUPUS ERYTHEMATOSUS
I. Gergianaki, C. Adamichou, G. Spyros, D. Bourmas (1,3), P. Vlachoyiannopoulos, A Tzioufas (Athens, Greece) (1) Irakleio (Greece), (2) Athens (Greece), (3) Nikosia (Cyprus)

OUTCOME OF CHILDHOOD LUPUS NEPHRITIS IN SAUDI CHILDREN
S. Al-Mayouf, A AlAmeer, A Alfattani, A Alsonbul (Riyadh, Saudi Arabia)

PHARMACEUTICAL DISRUPTION OF B2GPI CXCL4 COMPLEX USING COMPUTATIONALLY DESIGNED OLIGOPEPTIDES
M. Patsouras, E. Papakonstantinou, E. Eliopoulos, P. Vlachoyiannopoulos (Athens, Greece)

WHOLE TRANSCRIPTOME ANALYSIS OF APL TREATED HUVECS MAPS PROINFLAMMATORY AND PROCOAGULANT PATHWAYS
M. Patsouras, P. Karagianni, S. Foutas, E. Alexopoulou, M. Aggelopoulos, D. Thanos, A. Tzioufas, P. Vlachoyiannopoulos (Athens, Greece)

Impact of severe organic CNS involvement in cognitive function in a cohort of systemic lupus erythematosus patients, with the ACR-SLE battery
C. Golemati, E. Kampylafka, C. Papageorgiou, P. Vlachoyiannopoulos, A Tzioufas (Athens, Greece)

Anti-phospholipid antibodies are independently associated with atherosclerosis in the general population
M. Meroni (1), C. Selmi (1,2), E. Generali, M. De Santis, P.M. Battezzati, A. Ceribelli, M. Zuin (2) (1) Rozzano (Italy), (2) Milan (Italy)

Should we screen for atherosclerosis at an earlier age for women with systemic lupus erythematosus?
I. Saulescu, A. Borangiu, D. Opris-Belinski, S. Daia-Ilieescu, L. Groseanu, R. Ionescu (Bucharest, Romania)
LUPUS NEPHRITIS: SERIES OF 12 CLINICAL CASES IN A ROMANIAN REFERENCE CENTER

FEATURES ASSOCIATED WITH OUT-OF-HOSPITAL DEATH IN A GROUP OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DECEASED OVER A 10-YEAR PERIOD
I. Padjen, M. Erceg, M. Cerovec, M. Mayer, R. Stevanovic, B. Anic (Zagreb, Croatia)

FEMALE LUPUS PATIENT OPTIONS REGARDING TREATMENT AND NEGATIVE PREGNANCY OUTCOME
D. Opirs-Belinski (1), C. Ancuta (2), M. Pirvu (3), A. Balanescu (1), V. Bojinca (1), I. Saulescu (1), D. Mazilu (1), R. Ionescu (1)
(1) Bucharest (Romania), (2) Iasi (Romania), (3) Tg Mures (Romania)

AUTOANTIBODIES AS BIOMARKERS IN THE PREDICTION OF CLINICAL MANIFESTATIONS IN SYSTEMIC LUPUS ERITHEMATOSUS
A.N. Nistor, I. Scheip, M. Parvu, (Tg Mures, Romania)

LUPUS NEPHRITIS: CLINICAL MANIFESTATIONS AND RISK FACTORS
M. Kechida (1), N. Lorenzo Vilalba (2), R. Mesfar (1), Y. Alvarado Funes (2), R. Klii (1), S. Hammami (1), I. Khochtali (1)
(1) Monastir (Tunisia), (2) Belgium (Belgium)

TWO CASES OF THROMBOTIC THROMBOCYTOPENIC PURPURA IN PATIENTS WITH SLE
Z. Kardum, V. Prus, J. Milas Ahic (Osijek, Croatia)

PITYRIASIS LICHENOIDES ET VARIOLIFORMIS ACUTA (PLEVA) DEVELOPING DEPENDING ON THE USE OF HYDROXYCHLOROQUINE
S.E. Esmen, S. Arslan (Konya, Turkey)

LUPUS PREGNANCY: ACHIEVEMENTS AND OPEN ISSUES IN THE MULTIDISCIPLINARY MANAGEMENT
F. Crisafulli (1), L. Andreoli (1), L. Antolini (1), G. Parma (1), A. Lojacono (1), S. Zatti (1), V. Cappa (1), S. Calza (1), A. Tincani (1)
(1) Brescia (Italy), (2) Napoli (Italy)

Poster Tour 9A: Systemic Sclerosis and Raynaud phenomenon
Chair: V. Smith (Ghent, Belgium)

MACROVASCULAR IMPAIRMENT AND LIPID PROFILE IN SYSTEMIC SCLEROSIS PATIENTS
S. Paolino, E. Gotelli, V. Tomatis, B. Colombo, E. Alessandri, M. Ghio, C. Pizzorni, F. Goegan, M. Cutolo (Genoa, Italy)

PREDICTORS OF MORBIDITY AND MORTALITY IN PATIENTS WITH EARLY SYSTEMIC SCLEROSIS: LONG-TERM FOLLOW-UP FROM A SINGLE CENTRE INCEPTION COHORT STUDY
S. Panopoulos, V.K. Bournia, G. Konstantonis, K. Fragiadaki, P.P. Sfikakis, M. Tektonidoy (Athens, Greece)

VITAMIN D DEFICIENCY AND GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS. REAL LIFE DATA FROM A REFERRAL CENTER IN NORTHERN GREECE
I. Kostoglou-Athanassiou (1), L. Athanassiou (1), T. Banti (2), M. Gatsiou (2), C. Katsavouni (2), P. Athanassiou (2)
(1) Athens (Greece), (2) Thessaloniki (Greece)

OSTEOPROTEGERIN RELATES WITH BIOMARKER THAT HAVE ROLES IN OSTEOPOROSIS, FIBROSIS, AND VASCULOPATHY IN SYSTEMIC SCLEROSIS: A POTENTIAL MULTIFACETED RELATIONSHIP BETWEEN OPG/RANKL/TRAIL AND WNT INHIBITOR
A. Taylan, M. Birlik, G. Kenar, B. Toprak, A.R. Sisman (Izmir, Turkey)

PERIPHERAL BLOOD PERFUSION AND HAND DERMAL THICKNESS IN SYSTEMIC SCLEROSIS PATIENTS
B. Ruaro (1), A. Sulli (1), C. Pizzorni (1), S. Paolino (1), E. Alessandri (1), V. Smith (2), E. Gotelli (1), M. Patanè (1), M. Cutolo (1)
(1) Genoa (Italy), (2) Ghent (Belgium)
EVALUATION OF PERIPHERAL BLOOD PERFUSION IN PRIMARY RAYNAUD'S PHENOMENON AND IN SYSTEMIC SCLEROSIS PATIENTS
B. Ruaro (1), A. Sulli (1), V. Smith (2), S. Paolino (1), C. Pizzorni (1), A. Trombetta (1), M. Cutolo (1) (1) Genoa (Italy), (2) Ghent (Belgium)

A SIX MONTH FOLLOW-UP STUDY IN RAYNAUD'S PHENOMENON PATIENTS TREATED WITH AMINAPHTONE
B. Ruaro, S. Paolino, C. Pizzorni, M. Cutolo, A. Sulli (Genoa, Italy)

USE OF BIOELECTRICAL IMPEDANCE VECTOR ANALYSIS (BIVA) FOR THE ASSESSMENT OF BODY COMPOSITION IN A COHORT OF ITALIAN PATIENTS WITH SYSTEMIC SCLEROSIS
A. Rossi, A. Della Rossa, A. D'ascanio, S. Barsotti, S. Bilia, M. Mosca (Pisa, Italy)

NUTRITIONAL STATUS IN SYSTEMIC SCLEROSIS - A POSSIBLE ADDITIONAL TOOL IN ASSESSING DISEASE SEVERITY AND PROGNOSIS
M. Radic, D. Peric, D. Perkovic, D. Marasovic Krstulovic, K. Boric, D. Martinovic Kaliterna (Split, Croatia)

QUANTITATIVE COMPUTED TOMOGRAPHY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSIS: FACE AND CONTENT VALIDITY OF AN OPERATOR INDEPENDENT ALGORITHM BASED ON A FREE OPEN SOURCE SOFTWARE
A. Ariani, M. Silva (Parma, Italy)

IS IT POSSIBLE TO DISCRIMINATE A CLINICAL SUBTYPE OF SYSTEMIC SCLEROSIS ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION?
N. Yudkina, A. Volkov, T. Martynyuk, E. Nikolaeva (Moscow, Russia)

LUNG INVOLVEMENT PARAMETERS AND CLINICAL CORRELATIONS IN SYSTEMIC SCLEROSIS PATIENTS: A SINGLE CENTRE STUDY
A.C. Trombetta (1), E. Alessandri (1), S. Paolino (1), C. Pizzorni (1), M. Ghio (1), B. Ruaro (1), M. Patané (1), E. Gotelli (1), F. Goegan (1), A. Sulli (1), V. Smith (2), M. Cutolo (1) (1) Genoa (Italy), (2) Ghent (Belgium)

SERUM KLOTHO CONCENTRATION IS INVERSELY ASSOCIATED TO THE SEVERITY OF NAILFOLD CAPILLAROSCOPY PATTERN IN SYSTEMIC SCLEROSIS PATIENTS
R. Talotta (1), F. Rigamonti (1), T. Letizia (1), S. Bongiovanni (1), F. Atzeni (2), T. Vago (1), P. Sarzi-Puttini (1) (1) Milan (Italy), (2) Messina (Italy)

Poster Tour 9B: Systemic Sclerosis and Raynaud phenomenon
Chair: B. Ruaro (Genoa, Italy)

A LARGE-SCALE PROTEOMIC APPROACH IDENTIFIED NEW SERUM BIOMARKERS ASSOCIATED WITH SYSTEMIC SCLEROSIS
M. Meroni (1), M. De Santis (1), E. Generali (1), A. Ceribelli (1), N. Isailovic (1), M. Caprioli (1), G.M. Guidelli (1), C Selmi (1,2) (1) Rozzano (Italy) (2) Milan (Italy)

HOW MUCH TEMPERATURE CAN TRULY IMPACT ON RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS?
T. Schioppo, A. Orenti, P. Boracchi, O. De Lucia, A. Murgo, F. Ingegnoli (Milan, Italy)

HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH TWO DIFFERENT INTRAVENOUS ILOPROST REGIMENS
T. Schioppo (1), L. Scalone (1,2), P. Cozzolino (2), L. Mantovani (1,2), G. Cesana (2), O. De Lucia (1), A. Murgo (1), F. Ingegnoli (1) (1) Milan (Italy) (2) Monza (Italy)

THE D-PRO QUESTIONNAIRE: ASSESSMENT OF THE VITAMIN D STATUS IN SYSTEMIC SCLEROSIS PATIENTS
S. Paolino, V. Tomatis, E. Gotelli, E. Alessandri, M. Patane, A. Sulli, M. Cutolo (Genoa, Italy)

NAILFOLD CAPILLAROSCOPY ASPECTS IN UNDIFFERENTIATED CONNECTIVITIES TISSUE DISEASE RESULTS OF A PRELIMINARY STUDY
B. Neftia, S. Dahou, N. Bildi, F. Mechid, C. Dahou-Makhloufi (Algiers, Algeria)
DETERMINANTS OF QUALITY OF LIFE IN SYSTEMIC SCLEROSIS AND PATIENT PERCEPTION OF THE DISEASE

FERTILITY AND PREGNANCY IN SYSTEMIC SCLEROSIS – A EUSTAR CENTER EXPERIENCE

SCLERONET® A MULTICENTER PILOT PROJECT HEADED BY GILS – GRUPPO ITALIANO LOTTA ALLA SCLERODERMIA
B. Garbagnati, I. Galetti (Milan, Italy)

FUNCTIONAL STATE OF GASTROINTESTINAL TRACT IN CHILDREN WITH SYSTEMIC SCLEROSIS AND LIMITED SCLERODERMA
I. Chyzheuskaya, L. Belyaeva, H. Khrustaleva, H. Kolupaeva, T. Matsushko (Minsk, Belarus)

MODERN APPROACHES TO REHABILITATION OF CHILDREN WITH JUVENILE SKLERODERMA
I. Chyzheuskaya, L. Belyaeva, L. Zajtseva, H. Khrustaleva, H. Kolupaeva, A. Kolomiets (Minsk, Belarus)

ILOPROST INDUCED WEIGHT LOST AND MALNUTRITION IN SYSTEMIC SCLEROSIS PATIENT: A CASE REPORT
C. Bruno, S. Naty, L. Abenavoli, R. Grembiale (Catanzaro, Italy)

FACS CHARACTERIZATION OF CIRCULATING FIBROCYTES FROM LIMITED CUTANEOUS SCLERODERMA PATIENTS
R. Brizzolara, P. Montagna, S. Soldano, A.C. Trombetta, P. Contini, B. Ruo, S. Paolino, M. Cutolo (Genoa, Italy)

SYSTEMIC SCLEROSIS SINE SCLERODERMA
P. Athanassiou, C. Katsavouni, C. Gerodimos (Thessaloniki, Greece)
Abstract submission deadline: 15 December 2017

Due to many requests, the submission deadline has been extended to 18th December 2017

Abstract notification: 15 January 2018

Free Registration for presenters of accepted Abstract of these categories: Young Rheumatologists (under 40) and EMEUNET Members

**Submission**

Abstracts should be submitted **no later than December 18, 2017** by the online abstract submission.

Abstracts received by e-mail or by fax will not be considered: should you have any problems with the online submission please contact the Organizing Secretariat AIM Group International – AIM Italy (info@mediterraneanrheuma.com).

**Important notice for Presenting Authors**

Further to the Italian regulations for CME accreditation and for Continuing Medical Education – EACCME, please note that the abstract submission will be complete only when the following documents of the Presenting Author are provided:

- CV in European format of the Presenting author
- Disclosure form (for Continuing Medical Education - ITALIAN CME)

and the Conflict of Interest Disclosure Form (for Continuing Medical Education -EACCME)

of the Presenting author

In the closing phase of the online abstract submission area you will need to Upload both documents.

**DOWNLOAD AND FILL IN THE DOCUMENTS AVAILABLE ONLINE IN THE DEDICATED SECTION OF THE CONGRESS WEBSITE "SUBMIT THE ABSTRACT".**

http://www.mediterraneanrheuma.com/scientific-information/abstract/

**Notification**

Acknowledgement of receipt of the submission will be sent to the e-mail address stated under section "Personal details".

Notification on acceptance of the abstracts will be e-mailed by January 15, 2018. The registered author will receive all information concerning the abstract and is responsible for informing the other authors of the status of the abstract. The presenting author of the accepted abstract must register and attend the Congress.

**Instructions**

Upon submission, indicate your preferred presentation form (oral or poster) and one of the following category that best describes the abstract:
• Autoinflammatory and Rare Connective Tissue Diseases
• Gout and arthritis in dismetabolic conditions
• Osteoarthritis: Thermal and pharmacological management
• Osteoporosis/Osteomalacia and malabsorption
• Psoriatic arthritis / spondyloarthritis
• Rheumatoid arthritis
• Sjögren Syndrome and endocrine rheumatic disorders
• Systemic lupus erythematosus / Antiphospholipid syndrome
• Systemic Sclerosis and Raynaud phenomenon

Abstract Guideline
The complete abstract must not exceed 3.200 characters including spaces (approx. 350 words).
The electronical format is available from May 30th 2017.
Structured abstracts are mandatory. The abstracts should state clearly:
  > Purpose
  > Methods
  > Results
  > Conclusions

Tables, charts or other graphics could be included as only one image in jpeg format.
It is the author’s responsibility to submit a correct abstract; any errors in spelling, grammar or scientific fact will be reproduced as typed by the author, if accepted.
Please follow carefully the instructions reported in the online pages and fill in all the requested fields, in order to guarantee a correct and complete publication of the text.
Changes to abstracts can only be accepted until the deadline and can be added in the text using the User ID and Password received upon submission.

Oral Communication and Poster
The Scientific Committee will select the abstracts in order to allocate them in the sessions as oral presentation or as poster. Notification of acceptance or rejection will be sent to the corresponding author by January 15, 2018.
The presenting author of the accepted abstract must register and attend the Congress.

Publication of Contributions
All the abstracts submitted and accepted will be published in an issue of the Clinical and Experimental Rheumatology Journal and will be available on USB sticks.
You will be able to collect it at the registration desk.

Important notice for Authors
Information for authors submitting abstracts:
Further to the Italian regulations for CME accreditation, please be aware that the Abstracts accepted as Oral communications will appear on the Final Scientific Program exclusively with the name of the Presenting Author.
However, all the abstracts submitted in an issue of the Clinical and Experimental Rheumatology Journal (and available on USB sticks will be distributed on-site) will be fully published with the names of all the authors.

With regard to the accepted Posters they will fully appear with the names of all the Authors on both Final Scientific Program and the issue of the Clinical and Experimental Rheumatology Journal.
CME Credits

UEMS – European Union of Medical Specialists
An application has been made to the EACCME® for CME accreditation of this event.

ITALIAN CME – Continuing Medical Education
The Congress has been accredited by the National Commission for Continuing Education with the educational objective: Clinical Documentation. Clinical Training-Assistance Diagnostics And Rehabilitation, Assistance Profiles – Care Profiles (3), for the following disciplinary areas: Medical Surgeon (Disciplines: Rheumatology, Allergology and Clinical Immunology, Anatomic Pathology, Anaesthesia and Reanimation, Clinical Biochemistry, Cardiology, Dermatology and Venereology, Endocrinology, Clinical Pharmacology and Toxicology, Medical Genetics, Geriatrics, Food and Nutritional Hygiene, Respiratory Illnesses, Infectious Diseases, Metabolic Diseases and Diabetes, Sports Medicine, Physical Medicine and Rehabilitation, General Medicine, Internal Medicine, Legal Medicine, Thermal Medicine, Nephrology, Orthopaedics and Traumatology, Clinical Pathology, Paediatrics, Dietetics) ; Biologist; Dietician; Physiotherapist; General Nurses; Paediatric Nurses; for nr. 700 participants.

Participants exceeding or with different professions will not be entitled to credits. Credits will be recognized only upon presence at 90% of the scientific sessions.

CME credits: n. 4,2 – CME ID 93-218832 – ed.1

CME Provider
AIM Education – Provider n. 93
Via G. Ripamonti, 129
20141 Milan, Italy
Tel. +39 02 56601.1
Fax +39 02 70048585

cme@aimgroup.eu
www.aimeducation.it
GENERAL INFORMATIONS

VENUE

Built in 1926 and designed for storing goods, the “Magazzini del Cotone” building is Porto Antico’s main structure. Renovated in 1992 by architect Renzo Piano, these spaces are confirmed as one of the most popular locations for conventions, conferences and all types of events. A mix of innovation and tradition.

Inside the Porto Antico (Old Harbour) is the “Magazzini del Cotone” Conference Centre at the sea level with ample spaces and all possible solutions for big international events. An Auditorium of 1,480 seats, divisible into two mirror like rooms seating 740 each and a central stage designed as a theatre structure, adjustable to different heights perfect also for musical performances.

Thirteen modular rooms (2780 seats) and 8,500 square meters of exhibition space: charming rooms with views of the sea that adapt themselves to diverse fittings. The Conference Centre, fitted with the most advanced audio and video equipment, combines the charm of old architecture and modern and cutting-edge functionality.
How to reach the Venue

Porto Antico – Congress Centre “Magazzini del Cotone”
Tel. +39 010 2485626 – Fax. +39 010 2758929
www.centrocongressigenova.it

From Airport
- Taxi: about Euro 15,00 (one way)
- Bus: 30 minutes with shuttle bus Volabus Euro 6,00 (stop Piazza De Ferrari). Than from Piazza De Ferrari: subway to St. Giorgio Stop and than 15-minute walk, direction Porto Antico.

From Train Station Genoa (Piazza Principe)
- 15-minute walk direction Porto Antico
- Bus: 10 minutes, line 1 or 9, from Marittima Principe F.S. to Piazza Caricamento Terminal
- Subway: 5 minutes direction Brignole, San Giorgio Stop

From Highway
Exit from Genoa Ovest and take speed city motorway direction; after 3 km exit at Genoa Porto Antico; at the end of the road continue 50 m. and turn right at 2nd intersection to access Porto Antico.

Secretariat and Registration Desk
The on-site registration desks will be open during the following days:
- Thursday 12 April 2018 11.00 – 19.00
- Friday 13 April 2018 08.00 – 19.00
- Saturday 14 April 2018 08.00 – 13.00
Admission
Participants are kindly requested to wear their badge during all congress activities. The badge will admit to the scientific sessions, exhibition area, coffee breaks and lunch.

Language
The official language is English. No simultaneous translation will be provided.

Attendance Certificates
Attendance certificates will be delivered to all regularly registered participants at the end of the meeting.

Wi-Fi
Wi-Fi access is provided throughout the “Magazzini del Cotone” Congress Centre. To connect to the service, search your wireless networks and select MCR 2018. Following the online procedure you will enjoy of FREE Wi-Fi access during the congress.

Visa
All foreigners intending to enter Italy must provide the documentation required to justify the reasons and duration of their stay as well as, in some prescribed cases, the availability of adequate economic means and lodging.

In some cases you need a visa, application for which can be made at the Italian Diplomatic and Consular Representations in your country of residence.

Don’t you have an EU passport or EU valid documentation? Do you need a Visa?
If you have doubts visit NOW the website of the Italian Ministry of Foreign Affairs: http://www.esteri.it/visti/index_eng.asp
Find out whether, depending on your citizenship, country of long-term residence, and the duration and reasons for your stay, you need a Visa to enter Italy.
Find out which documents are required in order to apply for your visa.

ATTENTION:
VISA application may even require 120 days! Check it NOW
VISA application fee is from € 35,00 to € 116,00 per person to be paid at application, in local currency, to the Consulate or Embassy directly.
Presentation of the documentation requested does not necessarily ensure issuance of the VISA
AIM Group will be glad to assist you if you need any written invitation or other document to support your VISA Application. Feel free to contact us at visa@aimgroup.eu

GUARANTEE LETTER for CHINESE Citizen
If you are a citizen of China (RPC – 中華人民共和國 – 中华人民共和国) in accordance to the agreements between the Authorities you are demanded to obtain a guarantee letter issued by AIM Group as Local Organizer of the Conference. Please contact us at visa@aimgroup.eu for more instructions.
REGISTRATION

<table>
<thead>
<tr>
<th>REGISTRATION FEES (All fees are 22% VAT included)</th>
<th>Within 15 December 2017</th>
<th>Within 12 March 2018</th>
<th>From 12 March 2018 and onsite</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delegate</td>
<td>€ 350,00</td>
<td>€ 470,00</td>
<td>€ 530,00</td>
</tr>
<tr>
<td>Students/Trainée*</td>
<td>€ 150,00</td>
<td>€ 180,00</td>
<td>€ 210,00</td>
</tr>
<tr>
<td>Healthcare Professional**</td>
<td>€ 150,00</td>
<td>€ 180,00</td>
<td>€ 210,00</td>
</tr>
<tr>
<td>Patients***</td>
<td>€ 50,00</td>
<td>€ 50,00</td>
<td>€ 50,00</td>
</tr>
<tr>
<td>Young Rheumatologists (under 40) and EMEUNET Members ****</td>
<td></td>
<td></td>
<td>Free Registration</td>
</tr>
</tbody>
</table>

* In order to benefit from the special fee, a submission of your status confirmation (approval letter signed by the Head of Department or copy of your status ID) must be sent to the organizing secretariat by e-mail or by fax.

**Nurses, physiotherapists and occupational therapists. A letter of confirmation of your status from the Head of Unit or Institute must accompany the formal registration form.

*** For Patient sessions on nutrition and healthcare

**** Free Registration ONLY for presenters of accepted Abstract belonging to these categories: Young Rheumatologists and Fellows (under 40) and EMEUNET Members.

Free registration must be accompanied with certification issued by affiliated Institution/Department

Registration fees include:
- Admission to the scientific sessions
- Congress bag with complete meeting materials
- Certificate of attendance
- Access to the exhibition and poster area
- Coffee breaks and lunch, as indicated in the program

Name Changes
After March 12, 2018 sponsors who wish to make name changes will be charged of an handling fee of € 50,00 (VAT 22% included) per name change. A new registration form for each replacement participant will be required before the name change can be processed. Individuals may make name changes only in exceptional cases.

NETWORKING EVENING - Friday, April 13 2018
The Welcome Dinner will take place in the beautiful Villa Lo Zerbino in Genoa, on Friday, 13 April 2018.

Registration Cost
Each ticket costs **85,00€** starting from an aperitif and followed by a full course dinner, seating around tables and surrounded by the beautiful and antique rooms. Registration is now open!
**Venue**
**Villa Lo Zerbino**
Passo dello Zerbino, 1 - 16122 Genoa

**Parking Information**
Villa Lo Zerbino is very close to Piazza Manin, in the high side of the city and well connected to the city center through the large Via Assarotti. Due to the high turnout, we highly recommend to arrange car pooling or to come by taxi as the area does not provide a sufficient number of parking spots and cannot accommodate this need.

**Coming by car**
From A7-A10-A12-A26, exit Genova Est Distance from Genova Est exit: 2,6 km (8 minutes by car)
Once you’re out of the motorway, stay take the right and proceed straight on Via Bobbio. At the first cross (you can see a traffic light) stay on the right and take Via Montaldo on your right, proceed to the uphill for a couple of kilometers and take your right at the first rotunda. Now you’re in Piazza Manin, turn around the square and proceed stright after the traffic light. Then turn right and you’re in Passo dello Zerbino 1, when you’ll find the entrance of the villa.

**Cancellation Policy**
Notification of cancellation must be sent in writing to AIM Group International. Cancellations will be accepted until December 31, 2017 with a refund of all prepaid fees except for a 30% administration charge. No refunds will be made for cancellations received after this date.

**HOTEL**
For hotel reservation in Genoa, please note that AIM ITALY has been appointed as Official Housing Bureau of the XVII Mediterranean Congress of Rheumatology. For further information and reservations regarding Special Hotel Packages please see next section: [CONGRESS DELEGATE PACKAGES](#).

For any information and/or reservation please contact us at:
**AIM Italy**
Via Ripamonti 129 -20140 Milano
Ph + 39 02 566011
E mail: [info.hotel@mediterraneanrheuma.com](mailto:info.hotel@mediterraneanrheuma.com)
CONGRESS DELEGATE PACKAGES

<table>
<thead>
<tr>
<th>All fees are 22% VAT included</th>
<th>Within 15 December 2017</th>
<th>Within 12 March 2018</th>
<th>From 12 March 2018 and onsite</th>
</tr>
</thead>
<tbody>
<tr>
<td>Package A</td>
<td>€ 650,00</td>
<td>€ 750,00</td>
<td>€ 850,00</td>
</tr>
<tr>
<td>Package B</td>
<td>€ 550,00</td>
<td>€ 660,00</td>
<td>€ 720,00</td>
</tr>
</tbody>
</table>

All packages include registration fee and city tax

For Hotel reservation in Genoa, please note that AIM Group International has been appointed as Official Bureau of the XVII Mediterranean Congress.

Package A includes:
- Admission to the scientific sessions
- Congress bag with complete meeting materials
- Certificate of attendance
- Access to the exhibition and poster area
- Coffee breaks and lunches, as indicated in the program
- Hotel accommodation 4 stars for 2 nights taxes included (roulette formula)

Double Room: available just on request

(the difference in price and city tax for the accompanying person are not included, to be paid directly at the hotel)

Extra night/s: available just on request - Price per room per night is € 155,00

(€ 2 City Tax per person and per day is not included, to be paid directly at the hotel)

Package B includes:
- Admission to the scientific sessions
- Congress bag with complete meeting materials
- Certificate of attendance
- Access to the exhibition and poster area
- Coffee breaks and lunches, as indicated in the program
- Hotel accommodation 3 stars for 2 nights taxes included (roulette formula)

Double Room: available just on request

(the difference in price and city tax for the accompanying person are not included, to be paid directly at the hotel)

Extra night/s: available just on request - Price per room per night is € 130,00

(€ 1 City Tax per person and per day is not included, to be paid directly at the hotel)

The Organizing Secretariat AIM ITALY will be at disposal to suggest special package solutions for Students/Trainée, Healthcare Professional and Patients.

For any further information please contact AIM ITALY at:
ph. 0039 02 566011 e-mail info.hotel@mediterraneanrheuma.com

CONTACT

Organizing Secretariat

AIM Group International – Milan Office
Via G. Ripamonti, 129 – 20141 Milan, Italy
Ph. +39 02 566011 – Fax. +39 02 70048578
info@mediterraneanrheuma.com | www.mediterraneanrheuma.com
KEY DATES

ABSTRACT

ABSTRACT SUBMISSION DEADLINE
15 December 2017
Due to many requests, the submission deadline has been extended to 18th December 2017

ABSTRACT NOTIFICATION
15 January 2018

REGISTRATION AND PACKAGES

EARLY REGISTRATION DEADLINE
15 December 2017

LATE REGISTRATION DEADLINE
12 March 2018

ON SITE REGISTRATION
From 12 March 2018 and onsite
Visit the Congress website
www.mediterraneanrheuma.com
and watch the video with the interview performed by the Congress Chairman
Prof. Maurizio Cutolo
On behalf of the Board of the Mediterranean Congress of Rheumatology and of the Italian Society of Rheumatology